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SUMMARY
Pre-eclampsia is a multisystem disorder specific to pregnant women and is the major 
cause of maternal death in the United Kingdom today. The common pathophysiological 
feature of virtually all manifestations of pre-eclampsia is vascular endothelial 
dysfunction. This probably results from poor placental perfusion due to defective 
trophoblast invasion. Platelets and neutrophils play a role in the pathophysiological 
process; recruitment of these cells is mediated by cell adhesion molecule expression. 
Intrauterine growth restriction (lUGR) is often associated with pre-eclampsia. It too is 
associated with neutrophil activation.
The hypothesis examined in this thesis was that cell adhesion molecule 
expression, potential markers of endothelial damage and neutrophil activation, was 
increased in pre-eclampsia and lUGR. The following studies were performed:
1. Circulating concentrations of cell adhesion molecules were measured in normal and 
pre-eclamptic pregnancies.
2. Cell adhesion molecule mRNA and protein expression were determined in placentae 
from normal, pre-eclamptic and lUGR pregnancies,
3. Circulating concentrations of cytokines, known to activate neutrophils, were 
measured in normal and pre-eclamptic pregnancy and
4. The effect of the cytokine IL-6 on the expression of the cell adhesion molecules 
VC AM-2 and E-Selectin on human umbilical vein endothelial cells was determined.
Circulating concentrations of the cell adhesion molecules VCAM-1 and E- 
Selectin were increased in the maternal circulation of women with pre-eclampsia 
compared to normal pregnant controls. We found a difference in the expression of E- 
Selectin between plasma and serum suggesting that the wide range of concentrations of 
E-Selectin between patients may require large numbers of patients to show a significant 
trend. We found a higher expression of E-Selectin in serum compared to plasma in 
normal pregnant patients suggesting that more E-Selectin is shed into serum, after the 
activation of cells, due to clotting. Immunostaining for platelet endothelial cell adhesion 
molecule (PECAM) and intercellular adhesion molecule-1 (TCAM-1) was localised 
mainly to the endothelium of the stem villi, intermediate villi, terminal villi and 
decidual vessels. ICAM-1 staining was also evident in the stroma and fetal membranes. 
The placentae sections were negative for VCAM-1 and E-Selectin immunostaining. 
PECAM, IC AM-1 and ICAM-2 mRNA were all detectable in normal and pre-eclamptic 
placentae but E-Selectin and VCAM-2 mRNA were undetectable. There were no 
significant differences in the cell adhesion molecule mRNA expression or 
immunostaining in pregnancies complicated by pre-eclampsia or lUGR compared to 
normal pregnant placentae. The concentrations of the cytokines IL-6 and interleukin-1 
receptor antagonist (IE-Ira) were significantly higher in patients with pre-eclampsia
11
compared to normal pregnant patients whilst there were no significant differences in the 
concentrations of tumour necrosis factor alpha (TNFa), IL-8, granulocyte macrophage- 
colony-stimulating factor (GM-CSF) and IL-lp. IL-6 induced the expression of E- 
Selectin and VCAM-2 mRNA and protein on human umbilical vein endothelial cells, 
which was both time and dose dependent.
The presence of increased concentrations of VCAM-1, E-Selectin, IL-6 and IL- 
Ira may all contribute to the endothelial damage seen in pre-eclampsia and may explain 
the mechanism underlying leucocyte activation in this disorder. Management of pre­
eclampsia focuses on controlling blood pressure but effective treatment will only come 
as a result of a clearer understanding of the pathogenesis of the disease.
Ill
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CHAPTER ONE 
INTRODUCTION
Pre-eclampsia is a disorder specific to pregnant women which affects virtually every organ 
and system in the body. It remains the major cause of maternal death in the United 
Kingdom today (Dept, of Health et al. 1996). Hypertension and proteinuria, the traditional 
diagnostic features, represent only two facets of a complex pathophysiological process, the 
pathological feature being vascular endothelial dysfunction.
1.1 Hypertension in pregnancy
1.1.1 Definition and clinical aspects
Hypertensive disorders are the most common medical complications of pregnancy. There 
are three types of hypertension in pregnancy (Roberts et al. 1991). The first is hypertension 
in women who have hypertension predating pregnancy such as essential hypertensives. 
Secondly, hypertension may develop during pregnancy caused by another medical 
condition (e.g. phaeochromocytoma). Thirdly, there are women who are normotensive prior 
to pregnancy, who develop hypertension during pregnancy which subsequently remits 
within a few months of delivery. These woman have pregnancy induced hypertension 
(PIH). The most severe form of PIH is pre-eclampsia which occurs in 4-5% of pregnancies 
in the UK.
The internationally accepted definition of pre-eclampsia is a diastolic blood pressure 
of >90mm Hg after 20 weeks of pregnancy and proteinuria of >0.3g/24 hours (Davey & 
MacGillivray, 1988). Other associated findings include oedema, headache, hyperflexia, 
epigastric pain, fetal distress, placental abruption and increased uric acid levels. Eclampsia, 
the most severe form of the disease, is characterised by seizures (Friedman et al. 1991).
While microalbuminuria, measured by the albumin/creatinine ratio, may be a 
practical method to detect early renal involvement in hypertensive pregnancies, it is 
dependent on posture, time of day and excercise therefore standardisation of collection is 
important (Thong et al. 1991). A 24 hour urine collection remains the best method of 
monitoring proteinuria in pregnancy (Lindow & Davey, 1992),
A lack of knowledge regarding the aetiology of the disease contributes to the 
difficulties in treatment. Treatment involves the control of blood pressure with 
antihypertensive drugs and anti-convulsants to prevent seizures, but only delivery of the 
fetus and placenta will result in disease regression (Lowe & Rubin, 1992). Because delivery 
is often in the late second trimester, or early third, the child will be exposed to the problems
of immaturity. Studies relating the endothelial damage and dysfunction to platelet 
activation resulted in attempts to prevent or treat pre-eclampsia with anti-platelet therapy in 
the form of aspirin (Sibai et al. 1993; Loudon et al. 1989; Italian study of aspirin in 
pregnancy, 1993). Early small trials proved encouraging but the multicentre collaborative 
low dose aspirin study in pregnancy failed to support the administration of low doses of 
aspirin (CLASP, 1994). This is more fully discussed in section 1.11.
1.1.2 Effect on the fetus: Hypertension begins in utero
In addition to the hazards of prematurity pre-eclampsia is frequently associated with 
intrauterine growth restriction (lUGR). lUGR is the most common cause of late antepartum 
death of a normally formed fetus. Epidemiological evidence suggests that low birthweight 
is associated with elevated blood pressure in childhood and adult life, and involves a 
greater risk of mortality from cardiovascular disease (Barker et al. 1992b). Men and woman 
who had had a relatively low birthweight but a heavy placental weight were at the highest 
risk of developing hypertension. Barker et al (1992a) also concluded that reduced growth in 
fetal life was strongly related to high plasma concentrations of fibrinogen and factor VII 
which could be a persisting response to impaired liver development during a critical early 
period. Another study by Fall et al (1992) found that babies born 70 years ago, who were 
breast fed and weaned relatively late, had raised serum concentrations of low density 
lipoprotein cholesterol and increased death rates from ischaemic heart disease in adult life. 
A suggested cause of low birthweight is maternal malnutrition but Edwards et al (1993) 
also suggested that increased fetal exposure to maternal glucocorticoids was an alternative 
cause. They hypothesised that glucocorticoids, which act during critical periods of prenatal 
development, may exert effects or imprint responses which could persist throughout adult 
life. High concentrations of glucocorticoids in the fetus could affect the development of the 
fetal vasculature, since glucocorticoids modulate vascular tone, thus causing irreversible 
changes in the vascular structure.
1.1.3 Risk Factors
Pre-eclampsia is regarded as a disease of primigravidae (MacGillivray, 1958). With 
increasing parity underlying renal disease (or other medical condition) is more likely to be 
a cause of pre-eclampsia (Fisher et al. 1981). The risk of developing pre-eclampsia is also 
increased if the patient has a change in partner (Robillard et al. 1994). Pre-eclampsia is
linked to maternal age, there being a rise in incidence of the disease over the age of 35 
(Butler and Alberman, 1969). Multiple pregnancies, hydatidiform moles, diabetes mellitus 
(Howey and Baird, 1982) and a positive family history all increase the risk of developing 
pre-eclampsia (Chesley, 1978). A late spontaneous abortion, however, significantly reduces 
the risk of pre-eclampsia in a subsequent pregnancy (Campbell and MacGillivray, 1985).
1.1.4 Genetics of pre-eclampsia
Women have a genetic predisposition to develop pre-eclampsia which is possibly based on 
a single gene inheritance (Cooper & Liston, 1979; Sutherland et al. 1981; Chesley & 
Cooper, 1986). However because of the wide variatons in presentation of the condition, the 
mode of inheritance is still uncertain. The pathogenesis of pre-eclampsia is multifactorial 
involving coagulation, vascular reactivity or perhaps an immunological reaction between 
the mother and the fetus (MacGillivray, 1983). Some of these abnormalities may be 
determined genetically. Ward et al (1993) described a mutation in the angiotensinogen gene 
which seemed to be associated with an increased tendency to pre-eclampsia whilst 
Arngrimsson et al (1993) found a distortion in a region close to the angiotensinogen gene. 
The changes in the renin-angiotensin system in pre-eclampsia include a reduction in the 
levels of plasma renin activity, angiotensin II and aldosterone. However there are 
conflicting results reported in this area depending on the population studied (Morgen et al. 
1995). The incidence of pre-eclampsia in mothers, daughters, sisters and granddaughters is 
significantly higher than in mothers-in-law, daughters-in-law and in a control population 
suggesting that the condition is caused by maternal genes (Sutherland et al. 1981). 
Kilpatrick et al (1989) found that women who developed pre-eclampsia had an increased 
frequency of the gene HLA DR4 compared to normotensive pregnant woman. 
Susceptibility to the inheritance of this gene depended on a combination of fetal and 
maternal genotypes, involving a single recessive gene shared by the mother and the fetus. 
More research needs to be undertaken to create a clearer understanding of the genetics of 
pre-eclampsia.
1.2 Pathophysiological changes in pre-eclampsia
1.2.1 Uteroplacental bed and placenta
Physiological changes in the uteroplacental bed occur during normal and pre-eclamptic 
pregnancies. In normal pregnancy the maternal spiral aiteries undergo a number of changes
as the pregnancy advances. In the first trimester cytotrophoblasts penetrate the spiral 
arteries in the decidua of the uterus and migrate down these vessels invading the vessel 
wall. The endothelium is removed by these cells as well as the elastic lamina and muscular 
coat of the vessel, and they are replaced by fibrinoid material. By the end of the first 
trimester virtually every spiral artery will have undergone these physiological changes. In 
the early second trimester a second invasion of cytotrophoblasts occurs which converts the 
vessels supplying the placenta from muscular arteries into wide mouthed vessels. By doing 
this the vascular supply to the fetoplacental unit is converted from a high pressure low flow 
system to a low pressure high flow system. In this way the placenta and thus the fetus 
receive all the nutrients required for growth. However in pre-eclampsia only about half of 
the maternal arteries undergo these physiological changes (Khong et al. 1986). Not only is 
the primary invasion of trophoblasts partially impaired, but also the second invasion fails to 
occur or is inhibited (see figure 1). Therefore there is reduced placental blood flow which 
becomes critical with advancing gestation as the demands of the fetus increase. 
Furthermore, in pre-eclampsia the vessels retain their muscular coat and are sensitive to 
vasomotor stimuli. There is an increased build up of fibrin, platelets and lipid laden 
macrophages in some vessels. This defect is called acute atherosis which can lead to 
partially or completely blocked arteries (Labarrere, 1988).
The narrowed spiral arteries and placental ischaemia are a result of impaired 
trophoblast invasion. Cytotrophoblast expression of adhesion mlecules in pre-eclampsia is 
abnormal. Cytotrophoblasts fail to upregulate the expression of one integrin receptor which 
suggests that some trophoblast cells fail to differentiate properly (Zhou et al. 1993). 
Damsky et al (1994) reported that later gestation cytotrophoblasts, which have greatly 
decreased invasive capacity, are unable to upregulate the integrin alpha 1 beta 1, suggesting 
that this integrin is critical for cytotrophoblast invasion. Genbacev et al (1996) investigated 
whether lowering oxygen tension affected cytotrophoblast invasion. They found that 
hypoxia affected the progression of cytotrophoblasts through the cell cycle, their 
invasiveness being greatly reduced partly caused by alterations in integrin cell-extracellular 
matrix receptor expression (markers of transitions in the differentiation process). A study 
by de Groot et al (1996) found that women destined to have pre-eclampsia had lower 
circulating concentrations of insulin like growth factor binding protein-1 (a stromal 
protein). This was observed 12 to 26 weeks before the onset of clinical signs of the disease 
thus providing biochemical evidence that abnormalities of trophoblastic invasion may 
affect the maternal vascular deportation of the decidual stromal protein. This is further 
discussed in section 1.9.
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Figure 1. Cytotrophoblast invasion of the spiral arteries
A. Diagram of normal blood supply to the placenta. The radial arteries terminate into two spiral 
arteries. B. Diagram of abnormal blood supply to the placenta which occurs in preeclampsia. 
Physiological changes occur in some decidual segments of spiral arteries but are absent in others 
[reproduced from Khong et al (1993)]
1,2,2 Renin-angiotensin system
The renin-angiotensin system can change significantly in women with PIH. Plasma renin 
activity, angiotensin II and aldosterone levels are all reduced (Weir et al. 1973). However, a 
study measuring active renin, angiotensin converting enzyme and angiotensin II in placenta 
and fetal membranes by Kalenga et al (1996) showed that in moderate pre-eclampsia the 
activity of the renin-angiotensin system remained essentially normal. Broughton-Pipkin and 
Symonds (1986) suggested that the reduced perfusion of the uteroplacental bed stimulated 
the renin angiotensin system to increase blood pressure to improve perfusion, sometimes 
causing further damage. There may be a genetic link to the involvement of the renin- 
angiotensin system in pre-eclampsia. Inoue et al (1995) identified a genetic mutation at the 
site of renin cleavage in the angiotensinogen gene which significantly altered the reactions 
with renin and angiotensin-converting enzyme. They suggested that this mutation may 
predispose a carrier patient to the development of pre-eclampsia but because of the 
complexity of the renin-angiotensin system the physiological consequences of this mutation 
are not fully understood. The varying severity of disease in study groups proves to be a 
problem in studying the renin-angiotensin system in pre-eclampsia
1,2,3 Kidney
A number of pathological changes occur in the kidney in women with pre-eclampsia. The 
glomeruli enlarge and may bulge into the proximal tubule, which narrows the lumen. The 
changes in the glomeruli are termed glomerular endotheliosis (Spargo et al. 1959) and are 
found in 70% of women with pre-eclampsia in their first pregnancy. It has been noted that 
primary changes occur in the endothelial cells, but the mechanisms behind these changes 
are unclear (McCartney, 1964). The obvious clinical sign of glomerular dysfunction is 
proteinuria, a measure of disease severity. The increase in plasma uric acid levels precedes 
the presence of proteinuria and a decline in glomerular filtration rate is also indicative of 
glomerular damage and dysfunction (Gallery and Gyory, 1979).
1.2.4 Liver
Pre-eclampsia is the most common cause of hepatic pain and abnormal liver function tests 
in the pregnant patient. Hepatic lesions seen in pre-eclampsia include lake haemorrhage and 
areas of infai'ction and necrosis (Sheehan and Lynch, 1973). Haemorrhages arise in the 
arteries of the portal tract showing evidence of vascular damage. The hepatic lesions may 
be related to the activation of the coagulation system, endothelial damage and 
vasoconstriction. Biochemical evidence of hepatic dysfunction and damage is manifested 
by elevated liver enzymes. Occasionally jaundice occurs and may progress to hepatic 
failure producing vomiting, epigastric pain and tenderness. Weinstein (1982) derived the 
acronym HELL? (haemolysis, elevated liver enzymes and low platelet count) to describe 
29 patients with severe pre-eclampsia all of whom had these complications. Weinstein 
argued that HELL? syndrome was distinct from pre-eclampsia, although was part of the 
disease process. These complications may all be present even when blood pressure is not 
grossly elevated and management of HELLP syndrome patients usually requires urgent 
delivery, as in other forms of severe pre-eclampsia.
1.2.5 Brain
Cerebral involvement is the most frequent cause of death in pre-eclampsia/eclampsia 
(Sheehan and Lynch, 1973). The pathological features include cerebral oedema, cerebral 
haemorrhage, thrombotic lesions and fibrinoid necrosis, all reflecting vascular damage. 
Computerized tomography (CT) scanning of the brain in eclamptic patients often shows 
cerebral oedema but Richards et al (1988) proposed that the oedema was a secondary 
feature ocurring after seizures.
1.3 The Endothelium
1.3.1 Normal endothelial functions
Endothelial cell injury and altered endothelial cell function plays an important role in the 
pathogenesis of pre-eclampsia.
The vascular endothelium forms the lining of the circulatory system. Endothelial cells 
exist in a continuous monolayer which lines all blood vessels and constitutes the interface 
between the soluble and cellular components of the blood and vascular smooth muscle. The 
three main functions of the endothelium, particularly relevant to our understanding of pre­
eclampsia, are to maintain the integrity of the vascular system, to control vascular tone and 
to prevent intravascular coagulation (Friedman et ah 1991).
The endothelium acts as a semi-permeable membrane ensuring that nutrients, 
hormones and waste products remain intravascular until they are used by their target 
organs. The endothelial cells normally secrete vasodilatory agents, such as prostacyclin and 
nitric oxide (NO), but in response to certain stimuli, including hypoxia and vasoactive 
substances, the endothelial cells secrete vasoconstricting agents thus maintaining vascular 
tone. The endothelium can render itself thrombogenic by secreting von Willebrand’s factor 
(VWF), platelet activating factor and plasminogen activator inhibitor, which promote local 
coagulation and repair at the site of injury. These cells also produce prostacyclin and nitric 
oxide (NO) which inhibit the activation of platelets and neutrophils therefore preventing 
coagulation and vascular damage (see figure 2).
It has been suggested that problems in the understanding of pre-eclampsia are due to 
excessive attention being focussed on the blood pressure elevation and less attention to 
other pathological problems, especially endothelial cell dysfunction (Roberts et al. 1991).
1.3.2 Endothelial dysfunction in pre-eclampsia
There is considerable evidence that endothelial cell injury is present in women with pre­
eclampsia. Glomerular endotheliosis and structural changes in the placental bed and uterine 
boundary vessels provide morphological evidence of endothelial injury (Shanklin a & 
Sibai, 1989, Roberts et al. 1990). At a biochemical level an increase in VWF antigen, 
fibronectin and a disturbance in the prostacyclin/thromboxane balance all point to an 
injured endothelium.
1.3.3 Biochemical Changes
Fibronectin and VWF antigen are two factors known to be released from injured 
endothelial cells and are found to be increased in blood from pre-eclamptic women 
(Lockwood & Peters, 1990; Fournie et al. 1981). Roberts et al (1989) suggested that VWF, 
which mediates platelet adhesion to the endothelium, was a major marker of vascular 
endothelial cell damage and a change in maternal VWF might be related to the release of a 
factor or factors toxic to the maternal endothelium, secondary to reduced trophoblastic 
perfusion. Serum from pre-eclamptic women was thought to contain a factor(s) which was 
cytotoxic to endothelial cells in vitro (Rodgers et al. 1988). Early studies suggested that
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Figure 2. Schematic diagram showing the putative interaction between endothelin-1 (ET-1), 
endothelium derived nitric oxide (NO) and prostacyclin (PGI2) within the endothelium and 
vascular smooth muscle.
Production of ET-1 is stimulated by thrombin and other receptor-operated agonists (O). 
Released ET-1 can activate receptors on vascular smooth muscle mediating contraction 
(ETA-i’eceptors) and on endothelial cells releasing NO and PGI2 (ETg-receptors). 
Increases in cyclic GMP(cGMP) and cyclic AMP (cAMP) in endothelial cells evoked by 
the latter inhibit the production of ET-1. Also, vascular smooth muscle cells produce a 
putative inhibitory factor (IF) that reduces ET-1 production. At the level of vascular smooth 
muscle, both NO and PGI2 blunt or prevent ET-1 induced contraction (reproduced from 
Luscher et al. 1993).
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poorly perfused placental tissue released a factor(s) into the circulation which injured 
endothelial cells and set in motion a variety of problems including coagulation, 
vasoconstriction and intravascular fluid redistribution (Roberts et ah 1989). However, 
recent studies have shown that sera from pre-eclamptic women are not cytotoxic to 
endothelial cells. Zammit et al (1996) found that serum from pre-eclamptic women 
stimulated less endothelin production than serum from normal pregnant women but did not 
alter prostacyclin production and was not cytotoxic to endothelial cells. In a study by 
Endresen et al (1995) endothelial cells incubated with sera from pre-eclamptic women did 
not affect DNA or protein synthesis of the endothelial cells. Baker et ai (1996) 
hypothesised that in previous studies, which suggested that a factor in the maternal 
circulation caused activation of vascular endothelial cells, a static tissue culture 
environment was used. They showed that shear stress (a closer reflection of what was 
occurring in vivo) altered the effect of plasma on endothelial cells, showing no differences 
in the production rates of NO or prostacyclin in cells exposed to pre-eclamptic or normal 
plasma. The factor responsible for the increase in blood pressure appears to differ between 
women with pre-eclampsia and those with other hypertensive disorders of pregnancy but 
this factor has not been identified (Tsukimori et al. 1992).
When endothelial cells are damaged and the release of prostacyclin and NO is 
decreased, endothelin and endothelium derived constricting factors are released (Zeeman et 
al, 1992). Dekker et al (1991) studied endothelin levels in plasma from normotensive and 
pre-eclamptic women and suggested that the increased levels of endothelin in severe pre­
eclampsia were a consequence of extensive endothelial damage. Significantly increased 
levels of endothelin in plasma samples from women with pre-eclampsia were also found by 
Kraayenbrink et al (1993). However, Wang et al (1994a) found reduced urinary endothelin 
values in pre-eclamptic pregnancies, which may reflect impaired renal endothelin 
production, whilst Cervar et al (1996) suggested that pre-eclampsia was associated with a 
decreased release of endothelin-1 from trophoblastic cells in vitro. Gallery et al (1995) 
found no difference in endothelin levels in cells incubated in serum from normal and pre­
eclamptic women. Wang et al (1994b) studied the production of NO and endothelin from 
placental villi and found no differences in the production rates between normal and pre­
eclamptic placentae. Not all studies involving endothelin are consistent and further studies 
are required to clarify its role.
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1.3.4 Oxidative Injury
Further endothelial cell injury is caused by free radicals, which contain unpaired electrons 
in their outermost orbitals and are therefore extremely reactive. Free radical activity 
(oxidative stress) increases during normal pregnancy probably due to increased cell 
turnover (Zeeman et al. 1992). In pre-eclamptic patients the plasma concentrations of free 
radical oxidation products are higher even before the onset of symptoms. This shows a 
correlation with blood pressure. The unsaturated lipids and thiol-containing proteins in the 
cell membranes are susceptible to free radical attack (Wisdom et al. 1991). The un saturated 
fatty acids undergo oxidation by the superoxide anion (O2 -), which is cytotoxic to the cells. 
Neutrophils play an important role in the host defence against microbial infection. One of 
these defense mechanisms is the production of active oxygens, such as superoxide and 
hydrogen peroxide, which occur as by products during the degradation of purines to uric 
acid by xanthine oxidase (Many et ah 1996a). Hypoxia-reperfusion, cytokines and 
increased substrate availability all increase the activity of xanthine oxidase in pre­
eclampsia. Many et al (1996b) suggested that xanthine oxidase may increase the production 
of uric acid and contribute to the hyperuricemia and oxidative stress of pre-eclampsia. 
Placental production of lipid peroxides is abnormally increased in pre-eclampsia. The 
reason for this is not known but Wang and Walsh (1996a) hypothesised that if placental 
antioxidant enzymes were deficient, lipid peroxides would increase unchecked. They found 
significantly lower levels of superoxide dismutase and glutathione peroxidase in placental 
tissue from pre-eclamptics compared to normal pregnant women and speculated that the 
decreased antioxidant activity could result in increased lipid peroxide levels in pre­
eclamptic placentae. Since the placenta secretes lipid peroxides, this could be a source of 
increased lipid peroxides in the circulation of women with pre-eclampsia (Walsh et al. 
1996), Superoxide anions have been shown to inactivate NO and to reduce the production 
of prostacyclin, thus influencing vascular tone (Tsukimori et al. 1993). Also high 
concentrations of reactive oxygen species reorientates the arachidonic acid pathway in the 
cell from the production of prostacyclin towards thromboxane A2, thus stimulating platelet 
aggregation and vasoconstriction, causing endothelial cell dysfunction.
1.3.5 Prostacyclin and Thromboxane
The eicosanoid system plays an important role in the mechanisms involved in the 
development of pre-eclampsia. Prostacyclin (a potent vasodilator, inhibitor of platelet 
aggregation and stimulator of renin secretion by the endothelium) and thromboxane (a
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potent vasoconstrictor and platelet aggregating agent) influence the tone of placental and 
umbilical vessels in vitro (Chaudhuri et al. 1991).There is an increase in thromboxane and a 
decrease in prostacyclin production in the placenta in pre-eclampsia (Walsh, 1985). In 
normal pregnancy the placenta produces approximately equal amounts of prostacyclin and 
thromboxane whilst the pre-eclamptic placenta produces over seven times as much 
thromboxane as prostacyclin. The resulting imbalance between prostacyclin and 
thromboxane in pre-eclampsia contributes to the enhanced platelet activity and vascular 
damage. Factors in the sera of pre-eclamptic women cytotoxic to human endothelial cells 
could be responsible for the decreased prostacyclin production (Wang et al. 1992). 
Evidence suggests that elevated blood levels of lipid peroxidation products which disrupt 
membrane lipids and other cell components cause endothelial injury. Vascular contact with 
circulating peroxidating products directly cause dysfunction of the vascular endothelium by 
promoting the peroxidative damage of the endothelial cell membranes and selective 
inhibition of prostacyclin synthetase (Hubei et al. 1989). On the fetal side the production of 
prostacyclin from cord vessels is reduced in pre-eclampsia (Downing et ah 1980; Walsh et 
al, 1985).
1.3.6 Lipids
Normal human pregnancy results in a phenomenal physiological hyperlipidemia which 
involves a gestational rise in blood triglycerides and cholesterol (Potter and Westel, 1979). 
Women with pre-eclampsia display additional alterations in blood lipids which reflect on a 
disorder of lipid and lipoprotein metabolism (Kaaja et aL 1995). Lipid peroxides are 
increased in pre-eclampsia (Uotila et aL 1993) which could induce hepatic dysfunction, a 
frequent occurrence in pre-eclampsia. The lipid metabolism of women who develop pre­
eclampsia seems to be altered 10 to 20 weeks before the clinical onset of the disease. There 
are increased concentrations of circulating free fatty acids, increased concentrations of 
triglycerides, and also alterations in the fatty acid composition of circulating lipids 
(Lorentzen et aL 1994, 1995). Van den Elzen et al (1996) found a positive association 
between first trimester serum total cholesterol level and the chance of developing pre­
eclampsia. Hubei et al (1996) found that serum triglycerides and free fatty acids were 
increased in pre-eclampsia, and this correlated with the lipid peroxidation metabolite 
malondialdehyde. Endresen et al (1994) found that the free fatty acid, linoieic acid, 
impeded the ability of endothelial cells to produce prostacyclin and cGMP, and to inhibit
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platelet aggregation. These findings suggest that dysfunction in lipid and lipoprotein 
metabolism may contribute to endothelial cell dysfunction in pre-eclampsia.
1.3.7 Nitric Oxide
Endothelial cells modulate vascular tone. Acetyl choline acts on receptors on endothelial 
cells which release NO. This in turn stimulates guanylate cyclase in vascular smooth 
muscle to produce cyclic guanosine monophosphate which causes relaxation (Myatt et al. 
1991a). NO is a noxious stable, highly reactive free radical gas which was found to be a 
major messenger molecule that regulated immune function and blood vessel dilation. NO 
also serves as a neurotransmitter in the brain and peripheral nervous system (Lowenstein 
and Snyder, 1992). The NO system is widespread and is important in signal transduction 
and in immunological reactions (Chin et al. 1992). NO is labile, therefore direct 
measurements are difficult, so nitrates and/or nitric oxide synthase (NOS) are measured in 
the assessment of NO synthesis. L-arginine is converted to L-citrulline and NO by the 
enzyme NOS (Palmer and Moncada, 1989). NOS enzymes have been characterized and 
there may be up to six different isoforms (Pollock et al. 1991). Constitutive calcium- 
dependent isoforms of NOS are found in endothelial cells and brain and an inducible 
calcium-independent form is seen in macrophages, neutrophils and also in the endothelium 
(Knowles & Moncada, 1994). In blood vessels NOS is localised to the endothelial layers in 
large vessels. There is very little or no NOS in small arterioles and capillaries.
The role of NO in pregnancy has been widely assessed. NOS can produce superoxide 
as well as NO (Lowenstein and Snyder, 1992). This is significant in that NO is rapidly 
inactivated by superoxide anions and therefore a decrease in NO release in pre-eclampsia 
may be caused by an increase in oxygen free radicals (Zeeman et al. 1992). A major role of 
NO is to prevent the adhesion of platelets to endothelial cells and to prevent platelet 
aggregation. NO may help to prevent thrombosis formation in the fetus (Varela et ah 1992). 
In pregnancy, NO is generated in the human fetoplacental circulation contributing to the 
control of vascular tone and attenuating the actions of vasoconstrictors (Myatt et al. 1991b). 
A calcium dependent endothelial isoform of NOS has been characterised in the human 
villous vascular tree (Myatt et al. 1993). Immunohistochemical techniques have shown that 
endothelial NOS is localised to the endothelium of umbilical arteries and veins, chorionic 
arteries and veins and to the syncytiotrophoblast but not to the underlying cytotrophoblast 
and small fetal blood vessels (Buttery et al. 1994). Yallampalli and Garfield (1993) 
hypothesised that impaired vascular NO synthesis during pregnancy may be an important 
causal factor in pre-eclampsia. They infused an inhibitor of NOS, L-nitro-arginine methyl
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ester (L-NAME), into pregnant rats which caused hypertension and fetal growth restriction, 
without affecting gestation and concluded that an alteration in nitric oxide synthesis may be 
one of the factors responsible for pre-eclampsia. Ghabour et al (1995) found endothelial 
NOS staining in terminal villous vessels in pregnancies complicated by pre-eclampsia and 
lUGR but not in the terminal villous vessels from normal pregnancies. This contrasts with 
Morris et al (1995) who found lower NOS activities in villous tissue homogenates from 
pregnancies complicated by pre-eclampsia and growth restriction and who suggested that a 
reduction in NOS activity had a role in generating the high resistance fetoplacental 
circulation. Perfused umbilical vessels have a reduced ability to release NO in response to 
bradykinin in PIH (Pinto et al. 1991). This was in contrast to a study by McCarthy et al 
(1993) who found that the NO mediated component of endothelium-dependent relaxation 
was unaffected. However there was impairment of endothelium-dependent relaxation in 
arteries of women with pre-eclampsia compared to normotensive women. The reduced 
production of endothelial derived vasodilators may account for the increase in vascular 
resistance in pre-eclampsia. Cameron et al (1993) measured urinary levels of nitrites and 
nitrates (oxidation products of NO) in urine of normal pregnant and hypertensive pregnant 
women showing no significant difference between the two groups. We have recently shown 
that total nitrites are increased in the fetoplacental circulation but not in the maternal 
circulation in pre-eclampsia (Lyall et al. 1995b) and nitrites are also increased in the 
fetoplacental circulation in pregnancies complicated by lUGR (Lyall et aL 1996). Nobunga 
eLaL(1996) found increased levels of nitrate/nitrite in maternal plasma in pre-eclamptics 
compared to normotensive patients. However Davidge et al (1996) found that urine 
concentrations of nitrates and nitrites were significantly lower in pre-eclamptic patients 
compared to normal pregnant patients. They suggested that both plasma and urine nitrate 
and nitrite levels should be measured to address the possible impact of alterations in renal 
clearance of plasma NO metabolites from women with pre-eclampsia compared to normal 
pregnant women. Discrepancies amongst studies may be due in part to this reason, but also 
to inconsistency in patient populations and disease definitions. Endothelial NOS expression 
and NO production were increased in endothelial cells exposed to plasma from women with 
pre-eclampsia (Davidge et al. 1995; Baker et al. 1995). Sooranna et al (1996) suggested that 
expression of NOS was not different in placentae obtained from normal and pre-eclamptic 
women whilst Rutherford et al (1995) found increased NOS activity in first trimester 
placentae and pre-eclamptic and lUGR placentae but decreased NOS activity in the 
umbilical artery in pre-eclamptic and lUGR complicated pregnancies compared to normal 
pregnancy. They suggested that this reduction in NOS activity was indicative of endothelial 
dysfunction. The mechanism that gives rise to this increase in NO remains to be established
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but it may be a compensatory mechanism related to defective placentation. Myatt et al 
(1997a) found an increase in endothelial NOS staining in placentae from patients with pre­
eclampsia compared to normal pregnant patients and suggested that this increase in NO 
production may be due to a response to the increased resistance and poor perfusion in these 
pathological pregnancies. Myatt et al (1997b) found no difference in the staining of 
inducible NOS between patients with pre-eclampsia and control pregnant patients. N^,N*^ 
dimethylarginine (ADMA), an arginine analogue, inhibits NO synthesis and is found in 
significantly higher concentrations in patients with pre-eclampsia (Pickling et ah 1993). 
Ramsay et al (1994) studied the effect of intravenous glyceryl trinitrate (GTN), a donor of 
NO in vivo, on uterine artery blood flow in pregnancy and found that there was a decrease 
in resistance which could be beneficial to women with pre-eclampsia. Inconsistency 
between studies proves to be a problem in elucidating the role of NO in pre-eclampsia.
1.4 Coagulation System
When vascular damage occurs in pre-eclampsia fibrin is widely deposited, for example in 
acute atherosis or glomerular endotheliosis, suggesting that the coagulation system is 
activated (Davies and Prentice, 1992). Rather than being a primary component of the pre­
eclamptic process the activation of the coagulation system is more likely to be a secondary 
event. Douglas et al (1982) found that women with severe pre-eclampsia had elevated 
levels of fibrinopeptide A, which is a sensitive indicator of coagulation activation and a 
marker of thrombin generation. In pre-eclampsia there is an increase in factor VIII 
coagulant activity (Howie et al 1971, 1976) and also an increase in VWF (Redman et al. 
1977b) the latter reflecting endothelial damage by mediating platelet adhesion to the 
endothelium (Roberts et al. 1989). The fibrinolytic system is activated along with the 
activation of the coagulation cascade in pre-eclampsia. An increase in concentrations of 
fibrinogen-fibrin degradation products and fibrinogen-fibrin complexes as well as an 
increase in the fibrinopeptide BP 1-42 levels all provide evidence of fibrinolytic activation 
in severe pre-eclampsia. This can occasionally progress to full blown disseminated 
intravascular coagulation (DIG) in severe disease. In mild pre-eclampsia these changes are 
less striking but still occur suggesting that a similar process is occurring but perhaps to a 
lesser extent (Howie et al. 1971)." Borok et al (1984) suggested that fibrinolysis was more 
pronounced than fibrin formation in patients with severe pre-eclampsia. An increase in 
placental plasminogen activator inhibitor in severe pre-eclampsia suggests vascular damage 
which leads to thiombosis in the vessels in the placental bed (Estelles et ah 1987).
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1.5 Platelets
Platelets play a cmcial role in the pathophysiology of pre-eclampsia by promoting vascular 
damage and obstruction which leads to tissue ischaemia and further damage (Greer, 1992).
Normally thromboxane A2 and prostacyclin function as local hormones and are 
important in the control of the platelet-endothelial interaction. They act against each other- 
through the regulation of platelet adenylate cyclase, a controller of cAMP production and 
therefore platelet free calcium concentrations. Thromboxane A2 inhibits adenylate cyclase, 
which allows free intracellular calcium to rise. Meanwhile prostacyclin stimulates 
adenylate cyclase increasing cAMP which reduces free intracellular calcium and inhibits 
the activation of platelets.
In pre-eclampsia increased platelet reactivity may contribute to the obstruction of the 
uteroplacental microcirculation by platelet aggregation and by the release of vasoactive 
substances such as thromboxane A2- In pre-eclampsia the circulating platelet count is 
reduced (Redman et al. 1978) which reflects a reduced platelet life span, perhaps caused by 
a dysfunctional endothelial surface which induces an increased local consumption of 
platelets (Rakoczi et al. 1979). The reduced platelet count in women who develop pre­
eclampsia suggests that increased platelet consumption is an early feature of the disorder. 
An inverse relationship between the platelet count and fibrinogen-fibrin degradation 
suggests that the reduction in platelet count is due to increased platelet consumption which 
is associated with low grade DIG (Howie et ah 1971). In pre-eclampsia there is also an 
increase in the platelet specific protein (3-thromboglobulin, a marker of platelet activation in 
vivo (Redman et ah 1977a; Socol et al. 1985). This correlates with proteinuria and serum 
creatinine and suggests a link between platelet activation with renal micro vascular damage. 
Zemel et al (1990) measured the intracellular free calcium concentration in maternal 
platelets and detected a change that preceded the clinical manifestations of pre-eclampsia as 
early as the end of the first trimester. They showed that the increased sensitivity of platelets 
to arginine vasopressin may be a useful indicator of the subsequent development of pre­
eclampsia.
The platelet content of 5-hydroxytryptamine (5-HT) is reduced in pre-eclampsia. This 
is a vasoactive amine which is released when platelets aggregate and its loss indicates 
aggregation of platelets and stimulation of the platelet release reaction in vivo. Howie et al 
(1977) suggested that the platelets become activated in the microcirculation and release 
their products such as P thromboglobulin and 5-hydroxytryptamine. The platelets then re-
17
enter the circulation but are exhausted and cannot respond normally to aggregating agents. 
Platelet reactivity is increased in women with PIH (Greer et al. 1988) but is reduced in 
women with pre-eclampsia, the latter perhaps due to platelet exhaustion (Loudon et al.
1991). However, there are conflicting results between studies suggesting that platelet 
reactivity varies depending on the severity of the disease or the stage of the disease.
The changes in the coagulation system and in platelet function supports the concept 
that low grade DIG occurs in pre-eclampsia. Howie et al. (1976) described a coagulation 
'index' of serum fibrin-fibrinogen degradation products, platelet count and plasma factor 
VIII which correlates with an index of severity of the disease, from mild to severe pre­
eclampsia, therefore showing an association of the two conditions. All cases of perinatal 
death associated with pre-eclampsia had coagulation indices in the most severely abnormal 
range. These indices reflect the severity and progress of the disease.
1.6 Neutrophil Activation
When inflammatory mediators such as cytokines or thrombin are released neutrophils 
become activated and roll along the endothelium eventually flattening against the vessel 
wall. After diapedesis the activated neutrophil releases a variety of substances all mediating 
vascular damage. These include elastase, which destroys the physical integrity of the 
endothelial cell and inactivates NOS and cyclooxygenase, so reducing NO and prostacyclin 
production. Free radicals are also released which produce membrane lipid peroxides, 
causing lysis of the endothelial cells and increased vascular permeability and reactivity 
(Harlan, 1987). Leukotrienes are synthesized and released which also increases vascular 
permeability and promote further neutrophil activation and adherence (Bray, 1983).
Neutrophil elastase, free radicals and leukotrienes may therefore be a mediator of 
vascular damage and could contribute to the vascular lesion seen in pre-eclampsia. 
Neutrophil elastase substrates include elastin, collagen, fibrinogen complement and 
proteoglycans. It can therefore cause substantial tissue damage (Janoff, 1985). Greer et al 
(1989) found elevated levels of neutrophil elastase in pre-eclampsia but this was confined 
to the maternal circulation. However neutrophil activation also occurs in the fetal 
circulation during uncomplicated vaginal delivery. The mechanism behind this is so far 
unknown but may be due to a disturbance in the placental endothelium during labour 
(Greer et ah 1991b). Elastase positive neutrophils are found in increased numbers in the 
decidua of the placental bed (the site where the characteristic vascular lesion acute atherosis 
is seen) of women with pre-eclampsia (Butterworth et al. 1991). Pre-eclampsia is also
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associated with the presence of a neutrophil activator which enhances superoxide 
production. These mediators include peptide factors or other as yet unidentified metabolic 
products generated by the pre-eclamptic state (Tsukimori et ah 1993).
The activation of neutrophils in pre-eclampsia is likely to be a secondary 
phenomenon possibly triggered by immunological mechanisms which are implicated in the 
aetiology of pre-eclampsia (Stirrat, 1986). Neutrophils also interact with the platelet, 
coagulation and complement systems therefore indirectly causing vascular damage. There 
is a significant correlation between plasma neutrophil elastase and VWF which suggests 
that neutrophil activity may be responsible for the endothelial damage seen in pre­
eclampsia (Greer, 1991a). The mechanism of neutrophil activation is unknown but we 
previously reported that circulating concentrations of cell adhesion molecules and certain 
cytokines were increased in the serum from pre-eclamptic women (see sections 3.1.2 and 
3.3.2). The increased expression of these molecules on the endothelium may represent one 
of the mechanisms by which neutrophils are attracted to the endothelium where they 
contribute to endothelial dysfunction (Lyall et al. 1994; Greer et al. 1994).
1.7 Cell Adhesion Molecules
1.7.1 The role of cell adhesion molecules
Before neutrophils penetrate the endothelium and cause vascular damage they are 
selectively recruited to the endothelium, adhere to it and then move over the luminal 
surface of the endothelial cells. The attachment and extravasation of leukocytes is 
controlled by the expression of cell surface adhesion molecules on both the circulating cells 
and the vascular endothelium (Harlan and Liu, 1992). Increased expression of adhesion 
molecules by the endothelium could be responsible for the neutrophil activation which 
occurs in pre-eclampsia.
Cell adhesion molecules play a major role in maintaining the integrity of tissues and 
in controlling aggregation of leukocytes and platelets (Harlan and Liu, 1992). The 
endothelium controls the movement of molecules and cells between the blood and sites of 
injury. Circulating leukocytes (neutrophils, lymphocytes and monocytes) must become 
attached to a surface before they can migrate chemotactically. This is a crucial early step in 
mounting an effective inflammatory or immune response. The three general mechanisms of 
adhesion are the rapid transient upregulation of leukocyte adhesion molecules, the 
upregulation of endothelial adhesion molecules and more persistent cytokine activation of
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endothelial cells, leading to the synthesis of new adhesion molecules (Harlan and Liu,
1992). Endothelial cells lining the vascular endothelium possess leukocyte specific 
adhesion molecules constitutively and in response to a wide range of inflammatory 
mediators. The circulating leukocyte displays receptors for these endothelial cell adhesion 
molecules. The interaction of the cell adhesion molecules and their ligand fixes and flattens 
the leucocyte to the endothelium. The leukocyte then passes between the endothelial cell 
junctions and penetrates the basement membrane to the tissues. Normal regulation of 
endothelial cell adhesion molecules allows the endothelium platelets and neutrophils to 
promote coagulation and repair at the sites of injury. Therefore an increase in cell adhesion 
molecules provides an indication of inflammation/immune activity and/or endothelial 
damage or activation. Each endothelial cell adhesion molecule recognises a subset of 
leucocytes and is expressed according to an individualised time course in response to a 
subset of inflammatory mediators, or cytokines, such as interleukin-1 (IE-1), interferon 
gamma (IFNy) and tumour necrosis factor alpha (TNFa).
1.7,2 Cell adhesion molecule families
The three families of adhesion molecules relevant to our ar ea of research are the selectiiis, 
the immunoglobulin superfamily (IgSF) and the integrins. The selectins are involved in the 
earliest phases of a cascade of events leading to leukocyte extravasation. In regions of 
inflammation leukocytes move towards the edge of the capillary and begin to roll along the 
endothelium. P-Selectin (GMP-140) initiates the rolling of cells along the vessel wall, 
(Hogg et aL 1992), and this process is continued by E-Selectin (endothelial leukocyte 
adhesion molecule-1 or ELAM-1). The role of a third selectin, L-selectin, in leukocyte 
migration is, as yet, unclear. Each selectin may recognise not one but a number of 
carbohydrate ligands. Members of the IgSF function at different times during an 
inflammatory response. They include intercellular adhesion molecules-1 and -2 (ICAM-1 
and ICAM-2), the lymphocyte binding vascular cell adhesion molecule-1 (VCAM-1) and 
platelet endothelial cell adhesion molecule-1 (PECAM-1) or CD31. Members of the IgSF 
originally identified as adhesion molecules have diverse functions and in some cases the 
adhesion role is of secondary importance (Pigott and Power, 1993). Integrins are membrane 
glycoproteins expressed on diverse cell types. The activation of the leukocyte integrin 
receptors occurs after the downregulation of the selectin interactions. Integrin activation is 
triggered by molecules which are induced rapidly on the activated endothelium, e.g. platelet 
activating factor. Integrins bind to a wide variety of extracellular matrix proteins
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(fibronectin, fibrinogen, laminin, collagen and VWF) and to members of the IgSF. Most 
integrins bind to more than one ligand (Pigott and Power, 1993).
The cell adhesion molecules of interest in our studies were E-Selectin (ELAM-1), 
ICAM-1, ICAM-2, VCAM-2 and PECAM-1(CD31).
1.7.3 E-Selectin
E-Selectin is a cell surface glycoprotein, with a molecular weight of 95-115kDa. It is 
expressed by the cytokine activated endothelium and is involved in mediating the adhesion 
of blood neutrophils (Bevilacqua et ah 1989). Initial binding of neutrophils by E-Selectin is 
thought to trigger recruitment and activation of additional adhesion molecules to the site of 
inflammation (Pigott and Power, 1993). E-Selectin appears on the endothelium 
approximately 2 hours after exposure to the cytokines interleukin-1 (IL-1) and tumour 
necrosis factor a  (TNFa). It is induced more than 100-fold on human umbilical vein 
endothelial cells (HUVECS) by IL-1 or TNFa (Osborn, 1990). The ligands of E-Selectin 
are sialyl Lewis and related fucosylated N-acetyl lactosamines found on leukocyte 
glycolipids and glycoproteins (Pigott and Power, 1993).
1.7.4 ICAM-1 and ICAM-2
ICAM-1 and ICAM-2 on endothelial cells recognise their leukocyte ligand which enables 
the adhesion and migration of these cells out of the bloodstream. ICAM-1 contributes to 
both neutrophil and leukocyte adhesion in vitro. It is involved in a variety of other cell to 
cell interactions including lymphocyte aggregation and lymphocyte-fibroblast adhesion. 
ICAM-1 is a ligand for lymphocyte function associated antigen (LFA-1). High levels of 
ICAM-2 present on resting endothelial cells suggests that it is the major ligand for LFA-1. 
LFA-1 binds to both ICAM-1, which is inducible on the endothelium, and ICAM-2, which 
is present constitutively (Staunton et ah 1989). ICAM-2 is not upregulated by cytokine 
stimulation. LFA-1 plays a key role in mediating leukocyte adhesion to the endothelium 
during inflammatory responses through binding to ICAM-1. ICAM-1 and ICAM-2 account 
for all LFA-1 dependent adhesion to the either resting or activated endothelium. ICAM-1 
is important in adhesion and migration and is the major ligand for CD11/CD18. A 
CD ll/CD  18 dependent mechanism is necessary for neutrophil recruitment in response to 
infection. It is not clear what the roles of ICAM-1 and ICAM-2 are in neutrophil 
recruitment. However, ICAM-1 mediates adhesion of T-lymphocyte cells with antigen 
presenting cells or target cells and is involved in T-cell/T-cell and T-cell/B-cell
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interactions. ICAM-2 provides a co-stimulatory signal for T-cell activation and therefore 
may be important where the antigen presenting cells express little or no ICAM-1. ICAM-1 
is expressed basally on a variety of cell types including endothelial cells and monocytes but 
its expression is upregulated in response to specific stimuli such as cytokines. ICAM-1 is 
induced more than 30-fold on cultured HUVECS by interferon (IFN), IL-1 or TNFa. 
ICAM-1 is homologous to the neural cell adhesion molecule (NCAM) (Simmons et al. 
1988).
1.7.5 VCAM-1
Another member of the IgSF VCAM-1 is expressed on the luminal surface of cytokine- 
activated endothelium and binds lymphocytes, monocytes and eosinophils to activated 
endothelium using the integrin VLA-4 (very late antigen-4)(Hogg, 1992; Elices et aL 
1990). VCAM-1 expression on endothelial cells is induced by interleukin-1 p (IL-IP), 
interleukin-4 (IL-4), TNFa and IFNy (Masinovsky et al. 1990; Thornhill and Haskard, 
1990). VCAM-1 is present on the cell surface by 3 hours after cytokine stimulation and 
remains for at least 72 hours in the presence of cytokine. VCAM-1 has 7 immunoglobulin 
domains whilst an alternatively spliced form of VCAM-1 lacks domain 4 of the 7 
immunoglobulin domains (Hession et al. 1991) We have shown that serum concentrations 
of VCAM-1 and E-Selectin are elevated in pre-eclampsia (Lyall et al. 1994), which may 
reflect increased expression of these molecules on the endothelium, perhaps also reflecting 
on the contribution of these molecules to the endothelial dysfunction seen in pre-eclampsia.
1.7.6 PEC AM-1 (CD31)
PECAM-1 is expressed by trophoblasts and may act as a mediator at a molecular level of 
the adhesive interaction between trophoblasts and the endothelium. PECAM-1 is strongly 
expressed on T-cells adhering to endothelial cells and is constitutively expressed on 
endothelial cells. The precise role of PECAM-1 is not clear but it may play a role in 
adhesive events during thrombosis or wound healing and it has been implicated in the 
foraiation of cell-cell junctions within the placenta (Leach et al. 1993).
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1.8 Cytokines
Cytokines are regulatory molecules which act at short distances. There are numerous 
cytokines which can upregulate and downregulate adhesion in a very complex system. 
Cytokines may play a role in endothelial activation and may be responsible for many 
features of endothelial dysfunction. It is thought that cytokines such as TNFa, interleukin 
(IL)-6, IL-8, XL-Ip, IL-1 receptor antagonist (IL-lra), a naturally occurring inhibitor of ÏL- 
1, and granulocyte macrophage colony stimulating factor (GM-CSF) can trigger neutrophil 
activation, the expression of VWF and cell adhesion molecules on the endothelium, all 
resulting in endothelial damage. The two forms of IL-1, IL-a and IL-p, are both important 
mediators of the inflammatory and immune responses. They are produced primarily by 
mononuclear phagocytes (Dinarello, 1991a). IL-1 also acts on endothelial cells perhaps 
contributing to the development of atherosclerotic lesions, which aie seen in pre-eclampsia 
when acute atherosis occurs in the spiral arteries of the placental bed. The naturally 
occurring inhibitor of IL-1 is IL-ra which is produced by blood monocytes and tissue 
macrophages and plays an important role in many disease states (e.g. arthritis, diabetes and 
osteoporosis) [Dinarello, 1993]. IL-ip is involved in neutrophil adherance. IL-6 plays an 
major role in the mediation of inflammatory and immune responses and is produced by 
activated endothelial cells, monocytes and macrophages (Wong et al. 1988). We have 
shown recently that the concentration of the cytokine IL-6 is increased in the maternal 
circulation in pre-eclampsia (Greer et al. 1994). We have also shown that IL-6 increases the 
expression of VCAM-1 and E-Selectin on endothelial cells in vitro which suggests that IL- 
6 plays a role in increased cell adhesion molecule expression and also neutrophil activation 
occumng in pre-eclampsia. An increase in IL-6 and IL-ra suggests that increased cytokine 
concentrations may be responsible for the endothelial cell adhesion that occurs in pre­
eclampsia and furthermore endothelial dysfunction (Greer et al. 1994). IL-8 is a known 
chemoattractant and activator of neutrophils.
TNFa, a potent proinflammatory cytokine, is involved in inflammation, endothelial 
cell activation, shock and death (Dinarello, 1991a). Recently it has been suggested that 
TNFa plays an important role in pre-eclampsia and contributes to endothelial activation. 
However, Meekins et al (1994) found that circulating TNFa did not contribute to the 
initiation of endothelial cell activation that could be associated with the development of 
pre-eclampsia since the rise in circulating TNFa measurements was detected in 36% of 
cases with established pre-eclampsia, but this occurred after the syndrome was detected 
clinically. We have also found no significant difference in the concentration of TNFa in the 
plasma of pre-eclamptics compared to controls (Greer et ah 1994). Chen et al (1996) found
23
that TNFa mRNA expression was significantly elevated in pre-eclampsia. The half life of 
TNFa is only a few minutes and therefore it is not consistently present in the circulation 
(Van der Poll et al. 1990). A single blood sample may therefore fail to detect TNFa. Vince 
et al (1995) proposed that increased concentrations of TNF-receptors may be a better 
clinical marker of excessive TNFa release in vivo, rather than measurements of TNFa 
(because of its short half life). Vince et al (1995) hypothesised that in pre-eclampsia one or 
more factors derived from the placenta stimulate monocytes and/or neutrophils to produce 
TNFa which in turn causes endothelial dysfunction. GM-CSF is a specific glycoprotein 
which stimulates the formation of neutrophil macrophage and eosinophil lineage (Metcalf, 
1986).
1.9 The Placenta in Pre-eclampsia
During placentation physiological changes in the placental bed normally extend from the 
decidua into the inner myometrium (Fijnenberg et al. 1981). In pre-eclampsia the 
physiological changes are restricted to the decidual segments alone (Brosens et aL 1972). A 
complete absence of physiological changes throughout the entire length of some spiral 
arteries is seen in pre-eclampsia (Khong et al. 1986). Butterworth et al (1991) found an 
accumulation of elastase positive neutrophils in the decidua of pre-eclamptic placentae 
which may represent a secondary phenomenon after tissue ischaemia due to the inadequate 
maternal vascular response to placentation. It has been previously reported that neutrophil 
activation occurs in maternal plasma in pre-eclampsia (Greer et al. 1989). The release of 
neutrophil elastase could contribute to the vascular damage seen in the decidual region of 
the placenta. Recruitment and extravasation of neutrophils is partly mediated by the cell 
adhesion molecules expressed on the maternal endothelium and at the uteroplacental bed. 
We have recently shown that there is no difference in cell adhesion molecule expression in 
placentae from pregnancies complicated by pre-eclampsia and lUGR suggesting that 
neutrophil activation is confined to the maternal circulation as was previously reported 
/Greer et al. 1991a; Lvall et aL 1995a).
Macara et al (1995) demonstrated abnormalities in the development of the placental 
villous tree in pregnancies complicated by lUGR with and without preeclampsia (the 
structure of the placenta is shown in figure 3). However, there was no evidence to suggest 
that this abnormality was due to selective loss of small stem villous vessels but perhaps the 
abnormality lay within the nonmuscularised capillaries or the peripheral villi. The findings 
of Jackson et al (1995) were that growth restriction was associated with reduced large
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vessel wall thickness but again no reduction was found in the number of vessels per stem 
villous, suggesting that reduced villous development may contribute to abnormal umbilical 
artery blood flow in some cases of intrauterine growth restriction. These results contrasted 
with Wilcox and Trudinger (1991) who suggested that platelet activation within the small 
vessels of the stem villi played a role in placental insufficiency. Preterm small-for- 
gestational age fetuses showing abnormal umbilical artery Doppler waveform are at a high 
risk of perinatal death due to chronic fetal hypoxia. Macara et al (1996) examined the 
ultrastructure of the lUGR placentae to determine the likely origin of fetal hypoxia. 
Structural differences found in the terminal villi of the lUGR group, such as reduced 
cytotrophoblast proliferation and stromal fibrosis, were inconsistent with the view that the 
placenta is hypoxic in lUGR. They found a thickening in the basal lamina and congestion 
of the capillaries by erythrocytes both of which would limit oxygen transfer from the 
intervillous space to the fetus. Burton et al (1996) suggested that placentae adapt to hypoxic 
conditions by dilating the capillary sinusoids as well as thinning the villous membrane. 
Krebs et al (1996) found that the terminal villous compartment of the placenta from 
preterm intrauterine growth restricted pregnancies were maldeveloped, showing elongated 
villi and a wrinkled trophoblast surface with the occasional covering of a fibrin plaque. 
These findings may account for the impaired gas and nutrient transfer in this disorder.
The role of growth factors in pregnancy is a rapidly expanding subject. Implantation 
and growth of the placenta requires extensive angiogenesis to establish the vascular 
structures involved in exchange. Vascular endothelial growth factor (VEGF) is potentially 
an important regulator of angiogenesis, particularly during the extensive tissue growth and 
remodelling that occur in utero. VEGF may also play a role in term placenta when 
extensive angiogenesis diminished possibly regulating vascular permeability (Sharkey et al.
1993). Clarke et al (1996b) indicated that VEGF exerted a role within the placental villi and 
the maternal decidua in relation to growth, differentiation and migration of trophoblast, this 
being mediated primarily through the regulation of the receptor flt-1 (fms-like tyrosine 
kinase) rather than the KDR receptor (kinase -insert domain receptor). This contrasted with 
the views of Vuckoviv et al (1996) who suggested that VEGF was controlled through the 
KDR receptor. The presence of the growth factors, platelet-derived endothelial cell growth 
factor (PDEGF) and VEGF, in trophoblasts in early pregnancy are indicative of an active 
role for trophoblasts in the development of the villous vascular network (Jackson et ah 
1994; Shiraishi et al. 1996). Insulin-like growth factor (IGF) and IGF-binding protein 
(IGFBP) are used for cell to cell communication between fetal trophoblasts and maternal 
decidual cells at the feto-maternal interface for placental development or function (Han et 
al, 1996). Epidermal growth factor (EGF) produces a dramatic change in morphology and
25
Fetal um bilical vesse ls  
lying in W hartons jelly
T rophoblast covering 
chorion ic  vil>
and  lining intervillous
D ecidual p la te
M yom etrium
— C horion ic  p lo te  
tum
Amnion
Figure 3. The structure of the placenta
Only the fetal arteries are shown in the mid section, for clarity. The villi are much more 
finely branched [reproduced from Obstetrics by Ten Teachers (16th edition) editor 
G.V.P.Chamberlain, 1995, Edward Arnold, London]
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an increase in invasive capacity on first trimester cytotrophoblasts but this effect is reduced 
throughout gestation (Bass et ah 1994). Growth factors have an important part to play in 
pregnancy and further studies may help to elucidate this role.
1.10 Treatments
When considering the use of drugs in pregnancy clinicians must always be conscious that 
they are treating two patients. The control of the hypertension may be a useful short term 
treatment preventing the mother from the risks of high blood pressure such as stroke and 
allow the pregnancy to be prolonged for optimal timing of delivery. Such therapy may also 
allow for the administration of steroids to enhanee fetal lung maturity. Drugs commonly 
used to treat hypertension in pregnancy are the adrenoceptor antagonist labetalol, atenolol, 
methyldopa, calcium channel blockers and hydrallazine. Generally treatment starts with 
methyldopa or labetalol and a vasodilator such as nifedipine (a calcium channel blocker) or 
hydrallazine added. There is little evidence to suggest that any drug can affect the disease 
process once established.
It is very difficult to identify accurately which patients are likely to have eclamptic 
seizures even though most women have their first seizure whilst in hospital. 
Anticonvulsants have been used to arrest and prevent seizures. It is likely that the risk of 
seizures is reduced when blood pressure is controlled. Thus the role of prophylactic 
anticonvulsants is unclear although they are prescribed for fulminating disease. Diazepam 
is used to halt seizures. It can be used to prevent further convulsions but its side effects 
include respiratory depression, poor feeding and hypothermia in the neonate and it impairs 
the level of conciousness and suppresses respiration in the mother. So diazepam is not ideal 
for prevention. Other anticonvulsants include chlormethiazole and phenytoin. 
Chlormethiazole will suppress respiration and has to be carefully titrated against the 
patients concentration levels. It requires to be given in large volumes of fluid and may 
cause or contribute to fluid overload. Phenytoin has recently become popular being given 
intravenously. In the United States, magnesium sulphate is widely used as an 
anticonvulsant, probably working by reversing vasoconstriction (Belfort et al. 1992). A 
recent international multicentre randomized trial comparing standard anticonvulsants found 
that women allocated magnesium sulphate had a 52% lower risk of recurrent convulsions 
than those allocated diazepam, a 67% lower risk of recurrent convulsions than those 
allocated phenytoin, and women were less likely to require ventilation, to develop
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pneumonia and to be admitted to intensive care facilities than those allocated phenytoin. 
Babies of women allocated magnesium sulphate were less likely to need intubation or to be 
admitted to a special care nursery. This provides compelling evidence in favour of the use 
of magnesium sulphate for the treatment of eclampsia ( Duley et al. 1995).
1.11 Anti-platelet Therapy in Prevention of Pre-eclampsia
Pre-eclampsia is caused partly by endothelial dysfunction and is associated with platelet 
disturbance. Therefore, anti-platelet therapy might have a beneficial action in preventing 
the progression of the disease. Aspirin is the most effective agent available for clinical use 
in anti-platelet therapy. Aspirin irreversibly inhibits platelet cyclooxygenase activity, so 
blocking the synthesis of thromboxane. Small scale studies suggest that aspirin may be 
effective in the treatment of pre-eclampsia and lUGR. However, one problem is identifying 
the patients who will require such therapy, especially women with pre-eclampsia where 
those with severe disease are mainly primigravidae. The biggest potential concern 
regarding the use of aspirin in pregnancy was the problems caused if aspirin were to reach 
the fetus where it might impair haemostasis or lead to the closure of the ductus arteriosis. 
Jacobson et al (1991) studied the transfer of aspirin in the perfused human placental 
cotyledon but found no effect on the maternal or fetal circulation. A number of studies have 
shown that low doses of aspirin have a selective effect on maternal platelet function, 
sparing fetal platelet function and prostacyclin production and having no obvious effect on 
the ductus arteriosis (Ritter et al. 1987; Loudon et al. 1989). However Sibai et al (1991) 
found that patients on low-dose aspirin therapy had an increased risk of abruptio placentae 
which is a matter of concern although this was not found in the larger CLASP study.
There have been a number of studies examining the use of low-dose aspirin in the 
prevention of pre-eclampsia. Beaufils et al (1985) found a significant reduction in the 
incidence of pre-eclampsia and improved perinatal outcome. The incidence of growth 
restriction and fetal loss was also significantly reduced. However this study used small 
numbers of patients and the prognosis of the groups were not well matched. Another study 
by Wallenberg et al (1986) found a significant reduction in the development of 
hypertensive complications in women treated with low-dose aspirin. There was also a lower 
incidence of growth retardation but this was not significant. Many other small scale studies 
have been carried out but it is questionable whether these studies were large enough to 
assess accurately the benefits of aspirin in pre-eclampsia. The Collaborative Low-dose 
Aspirin Study in Pregnancy (CLASP, 1994), a much larger study, looked at the effects of
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60mg of aspirin or a matching placebo in 9364 women. Aspirin reduced the incidence of 
proteinuric pre-eclampsia by only 12%, which was not significant. There were no 
significant effects on the incidence of lUGR or of stillbirth and neonatal death. The Italian 
study of aspirin in pregnancy (1993) recruited over one thousand women at risk of pre­
eclampsia and found no differences in the outcomes measured. Sibai et al (19911 
administered aspirin to over three thousand women and although there was a 26% decrease 
in the incidence of pre-eclampsia this was not significant.
In conclusion, it appears that aspirin should not be used routinely in the prevention of 
pre-eclampsia. It may be have a place in high risk groups such as patients with 
anticardiolipin antibodies. Identification of patients, especially primigravidae, is a major 
problem and until objective techniques to identify these patients are available then 
antiplatelet therapy should not be routinely administered. The failure of antiplatelet therapy 
is likely to reflect the complex disease process of pre-eclampsia. Rational treatment of pre­
eclampsia will not be achieved until the pathogenesis of the disorder is fully understood.
1.12 Conclusions
Pre-eclampsia is a multisystem disorder which affects virtually all maternal organ systems 
and is manifested clinically as hypertension and proteinuria. The pathophysiological 
processes result from vascular damage and dysfunction which originate in the 
uteroplacental bed due to defective trophoblast invasion. The management of pre-eclampsia 
focuses on controlling blood pressure and monitoring the mother and the fetus to optimize 
the timing and the mode of delivery. However, effective diagnosis and treatment will come 
as a result of a clearer understanding of the pathogenesis of the disease.
1.13 Hypothesis
The hypothesis examined in this thesis was that cell adhesion molecule expression, a 
potential marker of endothelial damage and neutrophil activation, was increased in pre­
eclampsia and lUGR. The objectives were to measure the circulating concentrations of cell 
adhesion molecules and the cell adhesion molecule mRNA and protein expression in 
placentae from normal and pre-eclamptic pregnancies. We also measured the 
concentrations of circulating cytokines, known to activate neutrophils, in normal and pre­
eclamptic pregnancies and whether any of the cytokines had an effect on cell adhesion
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molecule expression on human umbilical vein endothelial cells. These objectives may 
identify possible mediators of vascular endothelial dysfunction and help to create a clearer 
understanding of the disease process in pre-eclampsia
CHAPTER TWO 
MATERIALS AND METHODS
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2 .1  GENERAL METHODS
2 . 1 . 1  Biochemicals
The following chemicals were purchased from the Sigma Chemical Company (Dorset, 
England); molecular biology agarose (gelling temperature 36°C), bovine serum albumin, 
bromphenol blue, dextran sulphate, diethylpyrocarbonate (DEPC), MR12 dowex mixed 
bed resin, ethidium bromide, 30% w/v hydrogen peroxide, Harris haematoxylin, 2- 
m ercaptoethanol, 3-[N -M orpholino] propane-sulfonic acid (M OPS), 
polyvinylpyrrolidone (PVP), salmon testes DNA, 2% silane, sephadex G-50, sodium 
acetate, tetramethylethylenediamine (TEMED), tris chloride, urea.
The following chemicals were purchased from BDH (Poole, England); acetic acid, buffer 
tablets (pH 4, 7.4 and 9.2), chloroform, decon 75, ethylene diaminetetra-acetic acid 
disodium salt (EDTA), formaldehyde, glycerol, hydrochloric acid, industrial alcohol, 
methylated spirit, methylated spirit phenol, propan-2-oI, sodium chloride, sodium citrate, 
sodium dodecyl sulphate (SDS), sodium hydroxide pellets, wax.
Ethanol, acetone and methanol (Analar quality) were purchased from Hayman Limited 
(Essex, England).
The following chemicals were bought from DIFCO (Surrey, England); agar, bacto agar, 
casamino acids, yeast extracts.
Phosphate buffered saline tablets (PBS) were purchased from ICN Flow (Irvine, 
Scotland).
Ficoll 400 was obtained from Phaimacia (Buckinghamshire, England).
Interleukin-6 was purchased from Genzyme (Kent, England).
2 . 1 . 2  General apparatus
2 . 1 . 3  Centrifuges
Glasgow Royal Infirmary: MSE Mistral 4L was purchased from Fisons (Sussex, 
England) and the Damon CRU 5000 centrifuge from Life Sciences (Hampshire, 
England).
Glasgow Royal Maternity Hospital: The Damon Clini-cool centrifuge was purchased 
from Life Sciences (Hampshire, England) and the MSE Chilspin from Fisons (Sussex, 
England).
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2 , 1 .4  M iscellaneous
The Scandinova (SLF 111) fridge, Blomberg freezer and the Proline microwave were 
purchased from Comet (Glasgow, Scotland). The -70°C freezer was purchased from 
Scotlab (Coatbridge, Scotland). The Corning magnetic stirrer, the Sartorius balance and 
the whirlimixer were obtained from BDH (Poole, England).
The Stanton fine balance was purchased from Fisons (Sussex, England).
2 . 1 .5  Radiochemicals
deoxycytidine 5'-[a32p] triphosphate triethylammonium salt (dCTP), 3000Ci/ml, was 
purchased from Amersham Life Science (Buckinghamshire, England).
2 . 1 . 6  General solutions and buffers
Distilled Deionised Water (ddH20)
All solutions and buffers were prepared using ddH^O, obtained from a Milli Q Plus water 
purification system purchased from Millipore S.A. (Molsheim, France). 500ml batches 
of ddH2 0  were autoclaved and stored at 4°C.
Concentrated (20x) sodium saline citrate (SSC)
175.3g sodium chloride and 88.2g sodium citrate were dissolved in 800ml of ddH^O. 
The pH was adjusted to pH7 with 5M hydrochloric acid. The solution was made up to 
IL, autoclaved and stored at 4°C. The final concentrations of sodium chloride and 
sodium citrate were 3M and 0.3M respectively.
Broth and agar
5g yeast extract, 5g sodium chloride, lOg casamino acids and 2ml IM sodium hydroxide 
were dissolved in IL of ddH20. 15g of bacto-agar was added to the above broth to make 
the agar. Both solutions were autoclaved immediately and stored at 4°C until use.
32
0.5M EDTA (pH8)
18.6g EDTA was dissolved in 80ml ddHzO. The pH was adjusted to pH8 with ION 
sodium hydroxide, and made to 100ml with ddHiO. The solution was autoclaved and 
stored at 4°C.
Tris EDTA (TE ) electrophoresis buffer
2.42g Tris Cl was dissolved in 4ml 0.5M EDTA (pH8) and made to 2L with ddH20 The 
pH was adjusted to pH8 and stored at RT. 500ml aliquots of this buffer were autoclaved 
and stored at 4°C for use as G50 column buffer.
Concentrated (5 Ox) Denhai'dt's reagent
Ig PVP, Ig ficoll and Ig BSA were dissolved in 80ml ddH20, stirred gently to avoid 
frothing and made up to 100ml with ddH20. The solution was then aliquoted in 5ml 
batches and stored at -20®C.
Concentrated (lOx) MOPS
41.2g MOPS was dissolved in 1600ml of O.IM sodium acetate (27.2g in 2L). The pH 
was adjusted to pH7 with ION sodium hydroxide. 20ml of 0.5M EDTA was added and 
the final volume and adjusted to 2L with ddH20. The MOPS buffer solution was 
autoclaved and stored at 4®C.
RNA loading dye
The RNA loading buffer consisted of SOOjxl formamide, lOpl 10% xylene cyanole, lOpl 
10% bromphenol blue, 4pl 0.5M EDTA and 176pl sterile glycerol. SOOpl of the loading 
buffer was added to 500|il glycerol and 500pl deionised formamide. 1 part of 10% 
ethidium bromide solution (1 mg/ml) was added to 2 parts of the dye solution, mixed and 
stored at -20^C.
Versene solution (pH7.2-7.3)
Versene was purchased from the University of Glasgow, Department of Virology. 80g 
sodium chloride, 2g potassium chloride, 11.5g sodium hydrogen phosphate, 2g EDTA
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and 15ml phenol red (1%) were dissolved in lOL of ddH20. The solution was 
autoclaved and stored at 4°C.
Trypsin solution
Trypsin was purchased from the University of Glasgow, Department of Virology. 8g of 
sodium chloride, 2ml potassium chloride (19%), O.lg sodium hydrogen phosphate, Ig 
dextrose and 3g tris amino methane, were dissolved in 700ml of ddH20. 1.5ml of phenol 
red (1%), penicillin (100,000U) and O.lg of streptomycin were added to this solution. 
The volume was made up to IL with ddH20 and 2.5g of trypsin was added. The solution 
was then autoclaved and stored at -20°C.
Trypsin/Versene solution
This solution contained 20ml of versene and 5ml of trypsin.
Deionised formamide
lOg dowex resin was added to 500ml formamide. This was stirred for Ih and then 
filtered. After aliquoting, the deionised formamide was stored at -70^C and used within 
three months.
Tris buffered saline (TBS) buffer
ION hydrochloric acid was added to 25ml 0.2M tris until a pH of 7.4 was obtained. This 
was made up to a final volume of 100ml with ddH20. The TrisHCl was added to 900ml 
of 0.9% sodium chloride to give the final solution.
2 . 1 . 7  Cell culture reagents and disposable apparatus
Fungizone (Amphotericin B, 250|Xg/ml)(F), Penicillin (lOOU/ml) and streptomycin 
(100|ig/ml) (P/S) were purchased from Gibco BRL (Paisley, Scotland).
Dulbecco's modification of Eagles medium DMEM (without L-glutamine, with 4.5g/L 
dextrose), heat inactivated foetal calf serum (PCS), L-glutamine (G) and heat inactivated 
horse serum (HS) were purchased from ICN Flow (Lvine, Scotland).
50ml centrifuge tubes, 6-well clusters and 10ml stripettes were purchased from Costar 
(Buckinghamshire, England).
8-well Labtek chamber slides were purchased from Gibco BRL (Paisley, Scotland),
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7ml bijoux containers, 30ml universal containers and 90mm petri dishes were purchased 
from BDH (Poole, England).
Collagenase (Type II), endothelial cell growth supplement (ECGS), 2% gelatin solution 
and heparin were purchased from Sigma Chemical Company (Dorset, England).
Sterile 0.22jam filter units were purchased from Millipore S.A. (Molsheim, France.)
All syringes, 18GA cannulas, 10% buffered formaldehyde and SOOmg vials of ampicillin 
were obtained from the Pharmacy, Glasgow Royal Infirmary.
2 . 1 . 8  General equipment for cell culture
The following is a list of general equipment used in cell culture;
BSB48 Laminar flow hood: ICN Flow (Irvine, Scotland).
Gallencamp CO2 incubator: Fisons (Sussex, England).
Olympus inverted microscope: Olympus (London,
England).
2 .1 .9  Molecular biology reagents and disposable apparatus
The Geneclean II kit was obtained from Stratech Scientific (Luton, England). The 
Oligolabelling kit was obtained from Pharmacia (Buckinghamshire, England). RNAzol™ 
was purchased from Biogenesis (Bournemouth, England). The blot transfer system, 
restriction enzymes and reaction buffers were purchased from Gibco BRL (Paisley, 
Scotland). Microcentrifuge tubes, sterile pastettes and pipette tips were purchased from 
Alpha Laboratories (Hampshire, England). Hybond-N transfer membranes were 
purchased from Amersham (Buckinghamshire, England). Blotting pads were bought 
from Gibco BRL (Paisley, Scotland).
The Magic Maxiprep and Magic Miniprep DNA purification systems were obtained from 
Promega (Southampton, England). Ultracomp E. coli (MC1061/P3) were bought from 
British Biotechnology (Oxon, England). DH5a competent cells and Ikb DNA ladder 
were obtained from Gibco BRL (Paisley, Scotland). DNA gel loading dye and the rabbit 
anti-human von Willebrand factor was purchased from Sigma Chemical Company 
(Dorset, England). The donkey anti-rabbit fluorescein was bought from Amersham Life 
Science (Buckinghamshire, England). The IL-6, IL-IRA, IL-6 receptor antibody, GM- 
CSF, IL-lp, TNFot and IL-8 Quantikine ELISA kits, the cell adhesion molecule 
antibodies PECAM, E-Selectin, VCAM-1 and ICAM-1 and the VCAM-1, ICAM-1 and 
E-Selectin ELISA kits were purchased from R+D Systems (Oxon, England). Aspergillus 
niger glucose oxidase antibody, biotinylated goat anti-mouse immunoglobulins (IgGs),
35
3,3’-diaminobenzidine tetrahydrochloride (DAB) and peroxidase conjugated streptavidin 
were purchased from DAKO Ltd (High Wycombe, England). The Vectastain kit and the 
Vectashield mounting medium was purchased from Vector Laboratories (Peterborough, 
England). Goat serum was obtained from the Scottish Antibody Production Unit (SAPU: 
Carluke, Scotland)
2 .1 .1 0  General equipment for molecular biology
The power supply, spectrophotometer and the gel electrophoresis apparatus (GlOO tank) 
were purchased from Pharmacia (Buckinghamshire, England).
The microcentrifuge and Grant water bath were obtained from Scotlab (Coatbridge, 
Scotland).
The Stuart Scientific shaker was purchased from BDH (Poole, England).
The Techne hybridiser and the transilluminator were purchased from Genetic Reseai'ch 
Instmmentation (Essex, England).
The UV Stratalinker was purchased from Stratagene (Cambridge, England).
Fuji X-ray film was obtained from Amersham (Buckinghamshire, England). 
Hypercassettes were obtained from Appligene (Durham, England).
Silica cuvettes were obtained from PSA (Loughborough, England).
The 32p p emitter monitor was purchased from Mini Instruments (Essex, England). The 
Histokinette 2000 was purchased from Medical Laboratory Equipment Services 
(Glasgow, Scotland). The Tissue Tek 3 and green uni-cassettes (to be used with this 
machine) were purchased from Bayer Diagnostics (Basingstoke, England).
2 .1 .11  General methods
All items of glassware were washed in solutions of decon 75 and were then rinsed in 
distilled water and dried at 50c*C.
2 . 1 . 1 2  Micropipetting
Volumes of solutions in the range of l-25ql were transferred accurately using digital 
pipettes from Scotlab (Coatbridge, Glasgow). lO-lOOOpl were transferred using Finn- 
pipettes purchased from Labsystems (Hampshire, England).
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2 .1 .1 3  pH measurement
Measurements of pH were carried out using a Kent 7020 pH meter purchased from BDH 
(Poole, England). This apparatus was regularly standardised using a solution of pH4, 
pH7 or pH9.2 prepared using buffer tablets.
2 .2  MOLECULAR BIOLOGY 
2 .2 .1  Antibiotics
The antibiotics used in the transfonnation of cells are shown in the following table:
Antibiotic Stock concentration Working concn.
ampicillin 50mg/ml In ddH20 50p.g/ml
tetracycline lOmg/ml in ethanol 30p.g/ml
Both antibiotics were stored at -20<^ C.
2 .2 .2  Transformation of Ultracomp E. coli.
Transformation involves treatment of the bacteria with divalent cations to make them 
temporarily permeable to small DNA molecules. In order to be able to select the bacteria 
that have been successfully transformed selectable markers are required. The most 
commonly used selectable markers are genes which confer resistance to antibiotics such 
as ampicillin and tetracycline (Sambrook, 1989).
The transformation of Ultracomp E. coli was carried out following the protocol 
accompanying the kit purchased from British Biotechnology. The competent cells were 
thawed on ice and mixed gently when the cell suspension was liquid. The cells were kept 
on ice at all times. lOOpl of cells were aliquoted into a pre-chilled 50ml polypropylene 
tube and 5\xl of a fresh dilution of 500mM mercaptoethanol in ddH20 was added. This 
solution was incubated for 10 min and was mixed gently every 2 min. 2|al plasmid DNA 
solution (approximately l|Xg/ml) was added and the tube swirled gently, and placed on 
ice for 30 min. Heat shock was performed by placing the cells in a 42°C water bath for 
75s and then returning to ice for 2 min. 900|xl SOC medium (provided with kit) was 
added and the solution then incubated at 37^C with moderate agitation (225 rpm) for 60 
min.
100ml agar was autoclaved, allowed to cool and separated into 2 x 50ml portions. 
To one portion the appropriate antibiotic was added. 4 plates each containing 25ml of
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agar were poured and allowed to set. Using a sterile wire, the E, coli were then streaked 
across agar plates. In some cases, with transformed cells, there was little growth on the 
agar plate containing the appropriate antibiotic and, in these cases, lOOjxl of transformed 
cells were streaked across the agar plate using a sterile bent glass rod. Untransformed 
cells were used as a control and spread onto 2 plates, with and without antibiotic. The 
plates were then incubated at 37°C overnight.
The results for a successful transformation were as follows 
Transformed cells + antibiotic = growth
Transfomied cells - antibiotic = growth
Untransformed cells + antibiotic = no growth
Untransformed cells - antibiotic -  growth
The colonies growing on the agar plate containing transformed cells were used for 
overnight cultures.
2 .2 .3  Transformation of DH5a E, coli.
DH5a competent bacteria, which had been stored at -70®C, were thawed on wet ice. l(il 
of the required plasmid DNA (500p,g/ml) was added to lOOjLil DH5a bacteria in a 
microcentrifuge tube and gently tapped. This solution was incubated on ice for 30 min. 
The cells were heat shocked by incubation at 42°C for 90s and then incubated on ice for 2 
min. After 0.5ml of broth was added the microcentrifuge tube was incubated for 1 hour at 
37°C in an orbital shaker at 225 cycles per min. Cells (lOOjxl) were either plated directly 
onto agar plates or a sterile wire loop was used to streak cells across the agar plates as in 
the transformation of Ultracomp E. coli. (section 2.2.2).
2 .2 .4  Overnight cultures
3 separate colonies from the agar plate containing transformed cells and the appropriate 
antibiotic were each added to 10ml of nutrient broth containing the appropriate antibiotic. 
A control transformation involved the addition of a colony from the plate with 
untransformed cells without addition of the antibiotic to the nutrient broth. Cultures were 
shaken at 225 cycles per minute overnight in an orbital shaker at 37°C. No growth was 
apparent in the control nutrient broth whereas the solution in the other 3 universals was 
turbid. The cells from these overnight cultures were used for the small scale plasmid 
DNA preparations.
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2 .2 .5  Plasmids
Details of plasmids used in this study:
The 1.2kb E-Selectin complementary deoxyribonucleic acid (cDNA) in the CDM-7 
plasmid was kindly donated by M.P. Bevilacqua, Howard Hughes Medical Institute, 
University of California, San Diego, La Jolla, California, U.S.A. The plasmid was 
amplified in MC1061/P3 cells (competent E. colL) and excised using the restriction 
enzyme Xba 1.
The l.Bkb ICAM-1, 800b ICAM-2, 1.9kb VCAM-2 and 2.5kb PECAM cDNA, all 
in the plasmid pCDM-8 were all grown in MC1061/P3 cells and excised using the 
restriction enzymes Xba-1 and HIND-IIL These were kindly donated by Dr David 
Simmons, Cell Adhesion Laboratory, Imperial Cancer Research Fund, Institute of 
Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, U.K.
2 .2 .6  Small scale preparation of plasmid DNA
The components required for this procedure were supplied in the Magic Minipreps DNA 
Purification System kit.
3ml of the most turbid overnight culture of cells were pelleted using a 
microcentrifuge (13,000 rpm for 20s at room temperature [RT]). The cell pellet was 
re suspended in 200pl of Cell Resuspension Solution (50mM Tris HCl, pH 7.5; lOmM 
EDTA; lOOpg/nal RNase A). 200pl of Cell Lysis Solution (0.2M NaOH, 1% SDS) was 
added and the tube was inverted several times to mix. The cell suspension cleared almost 
immediately. 200jxl of Neutralization Solution (2.55M potassium acetate, pH 4.8) was 
then added and the tube mixed. Following centrifugation at 10,000 r.p.m. for 5 min at 
4°C the clear supernatant was decanted to a new microcentrifuge tube. 1ml of the 
Purification Resin was added to the supernatant and the two mixed.
For each miniprep a 3ml disposable syringe was required. The plunger from the 
syringe was removed and the syringe barrel was attached to the minicolumn which was in 
turn attached to a vacuum pump. The resin/DNA mix was pipetted into the syringe barrel. 
A vacuum was applied to pull this mix into the minicolumn. 2ml of Column Wash 
Solution (200mM NaCl; 20mM Tris HCl, pH 7.5; 5mM EDTA-diluted 1:1 with 95% 
ethanol) was added to the syringe barrel and a vacuum applied. The resin was dried by 
drawing a vacuum for a further 2 min. The syringe barrel was removed and the 
minicolumn transferred into a 1.5ml microcentrifuge tube. To remove any residual 
Column Wash Solution the minicolumn was spun in a microcentrifuge at 10,000 rpm for 
20s at RT. The minicolumn was then transferred to a new microcentrifuge tube and 50|il 
of TE buffer (preheated to 70°C) was added. After 1 min the DNA was eluted by
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centrifugation of the minicolumn for 20s at 10,000 rpm at RT. The plasmid DNA was 
stored at -20°C.
2 .2 .7  Large scale preparation of plasmid DNA
To 500ml of nutrient broth, 2ml of the overnight culture used for the mini preparation 
was added, along with the appropriate antibiotic. This solution was shaken at 225 cycles 
per minute overnight in an orbital shaker at 37°C. The resulting cloudy solution was then 
used to carry out the Promega Magic Maxipreparation protocol.
The components required for this procedure were supplied in the Magic 
Maxipreparation DNA purification system kit. 500ml of an overnight culture of E. coli 
were spun at 14,000g for 15 min at 4^0. The cell pellet was resuspended in 15ml of Cell 
Resuspension Solution and then divided equally into duplicate centrifuge tubes. All 
subsequent steps were conducted in duplicate. 7.5ml of Cell Lysis Solution was added 
and the solution mixed gently. The cell suspension appeared clear and viscous. 7.5ml of 
Neutralization Solution was then added, the solution mixed immediately, and centrifuged 
at 14,000g for 15 min at 4°C. The supernatants were decanted into new centrifuge tubes 
(avoiding the white precipitate) and 0.6 x volume of isopropanol (approximately 11.4ml) 
was added. After mixing, the solution was centrifuged at 14,0D0g for 15 min at 4°C. 
The DNA pellet was resuspended in 2ml of TE buffer. Next 10ml of well mixed 
Purification Resin was added to the DNA solution and transferred to the maxicolumn 
inserted into the vacuum pump. A vacuum was applied to pull the mix into the column. 
13ml of Column Wash Solution was added to the tube containing the DNA/Resin mix 
and poured into the column and a vacuum applied. A further 12ml of Wash Solution was 
then added followed by 5ml of 80% ethanol. The resin was dried by drawing a vacuum 
for 10 min. After removing the column from the vacuum it was placed in the 50ml screw 
cap tube provided and 1.5ml of preheated (70^C) TE buffer was added and incubated for 
1 min. The DNA was eluted by spinning the column in the 50ml tube at 1300g for 5 min 
at 4^C. The DNA was stored at -20°C.
2 .2 .8  Freezing transformed cells
The following protocol was used to freeze and store cells for future use;
8.5ml of transformed cells were added to 1.5ml sterile glycerol. The solution was well 
mixed and then aliquoted into 1ml batches. These aliquots were frozen using an 
ethanol/dry ice bath and stored at -70°C.
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2 .2 .9  Quantification of DNA and RNA
5|il of the DNA/RNA sample was added to 995|Ll1 of ddH20 in a microcentrifuge tube. 
This solution was vortexed and transferred into a silica cuvette using a pastette. The 
absorbance of the solution at 260nm and 280nm was measured using a 
spectrophotometer. The absorbance of the solution at 260nm and 280nm is directly 
proportional to the concentration of RNA and DNA present in the sample. The ratio of 
absorbance values obtained (i.e. A260/A280) is an index of the purity of the RNA sample. 
The ratio can vary, however, a ratio of 2.0 represents a pure RNA sample with veiy little 
protein contamination. The amount of DNA present in 1ml of a sample was calculated 
by multiplying the absorbance at 280nm by 50 since an optical density of 1 represents 
50mg of DNA. The amount of RNA present in 1ml of a sample was calculated by 
multiplying the absorbance at 260nm by 40 since an optical density of 1 represent 40mg 
of RNA. The total amount of DNA/RNA present in a sample was calculated by 
multiplying the above value by the dilution factor.
2 .2 .1 0  Digestion of plasmid with restriction enzymes
React 2 (provided with the enzyme) was the reaction buffer required when the cDNA E- 
Selectin, PECAM-1, ICAM-1, ICAM-2 and VCAM-2 were digested.
To digest E-selectin, lOpl cDNA, 2pl Xba-1, 2\il React 2 (xlO) and 6jil ddH20 were 
combined and incubated at 37°C overnight.
For the other cDNA, lOpl cDNA, 2jil Xba-1, 2pl HIND III, 2jxl React 2 (xlO) and 4pl 
ddH20 were combined and incubated at 37°C overnight.
After incubation a lOfxl aliquot of each sample was electrophoresed on a DNA gel to 
ensure that the cDNA had been excised from the plasmid.
2 .2 .1 1  DNA gels
0.8g of agarose was dissolved in 100ml of TE buffer and the solution was microwaved 
to dissolve the agarose. The flask was gently swirled every 20s to ensure even 
dissolution. IjLil of ethidium bromide (lOmg/ml) was added to the solution which was 
then allowed to cool slightly. The solution was poured into a gel plate which contained a 
plastic comb, was allowed to set and was then placed into a G-lOO gel tank and 
submerged in TE buffer. 2pl of DNA loading dye was then added to each sample before 
loading into the wells of the gel. The DNA samples were electrophoresed at 60V for 2- 
3h. All cDNA inserts were excised from the gel using a clean scalpel blade and then 
extracted from the agarose using the gene cleaning kit.
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2 .2 .1 2  Gene cleaning
The components required for this procedure were supplied in the Geneclean II kit.
Each gel slice was placed in a microcentrifuge tube which was subsequently filled 
with sodium iodide. This was placed at 5Q°C for 5 min until the gel slice had dissolved. 
(Depending on the size of the gel slice it could take between 5-9 min to dissolve.)
The "glass milk" (silica matrix) was resuspended thoroughly and lOpl was then 
added to the dissolved gel slice and vortexed. This was incubated on ice for 5 min. The 
microcentrifuge tube was then spun at 13,000 rpm for 10s at RT. After the supernatant 
was removed, 200p,l of NEW solution (which contained NaCl, Tris, EDTA, H2O and 
ethanol) was added to the pellet. This was resuspended thoroughly using a 200jil pipette 
tip. The microcentrifuge tube was spun again at 13,000 rpm for 10s at RT and the 
supernatant removed. Another 200p.l of NEW solution was added and this step was 
carried out twice more. 50^ 11 TE buffer was added to the pellet, resuspended thoroughly 
and incubated at 50°C for 3 min. After a 30s spin at 13,000 rpm at RT in the 
microcentrifuge the supernatant, which contained the eluted DNA, was removed. A 
further 50|xl TE buffer was then added to the pellet and resuspended well. Again after a 
30s spin at 13,000 ipm at RT the eluted DNA was removed in the supernatant.
5pl of gene cleaned DNA and Ijil of Ikb DNA (500bp-12kb) ladder were 
electrophoresed on an agarose gel to check the correct size of insert required was obtained 
(figures 4, 5 and 6 ). The DNA was then aliquoted into 50ng batches and stored at -20^C.
2 .2 .1 3  Northern analysis
When preparing RNA from human umbilical vein endothelial cells (HUVECS) RNAzol 
B (lml/9.5cm^)was added directly to the cells. The solution was then triturated and 
transferred to a microcentrifuge tube containing 100ml chloroform. This tube was 
vortexed and incubated on ice for 5 min.
When preparing RNA from frozen blocks of placenta the tissue was ground into 
fine particles using a mortar and pestle, ensuring the tissue was kept frozen, i.e. 
submerged in liquid nitrogen at all times. Once ground, 2ml of RNAzol B was added for 
every O.lg of tissue, and the resulting solution was homogenised (2xl0s at setting 8 on 
the dial). 1ml batches of this solution were added to lOOpi aliquots of chloroform, 
vortexed and incubated on ice for 5 min. The tubes were spun in a microcentrifuge at
13.000 rpm for 15 min at 4°C. The upper layer was removed and an equal layer of 
isopropanol was added (approximately 500)0.1). The sample was spun for 30 min at
13.000 rpm at 4°C, after which the supernatant was removed and the pellet drained by 
inverting the tube on a tissue. 500)Ol of 70% ethanol was then added to the pellet and the 
RNA was stored at -70°C until the next step could be performed. The RNA was spun at
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Figure 4. Scan of a DNA gel containing:
Lane I - gene cleaned 1.2 kb E-selectin cDNA excised with Xba-1 
Lane 2 - uncut E-selectin plasmid 
Lane 3 - Ikb DNA ladder
Lane 4 - gene cleaned 1.8kb ICAM-1 cDNA excised with Xba-1 and 
HIND-IM 
Lane 5 - uncut ICAM-1 plasmid 
The samples were run against a Ikb cD N A  ladder and their length calculated by 
comparing their positions on the gel to the bands o f the cDNA ladder
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Figure 5. Scan of a DNA gel contaning:
Lane I - gene cleaned 800b ICAM-2 cDNA excised with Xba-1 and 
HIND-III 
Lane 2 - uncut ICAM-2 plasmid 
Lane 3 - Ikb DNA ladder
Lane 4 - Gene cleaned 2.5kb PECAM cDNA ladder excised with Xba- 
I and HIND-III 
Lane 5 - uncut PECAM plasmid 
The samples were run against a Ikb cDNA ladder and their length was calculated by 
comparing their positions on the gel to the bands o f the DNA ladder.
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Figure 6. Scan o f DNA gel containing:
Lane I - gene cleaned 1.9kb VCAM-2 cDNA excised with Xba-1 and 
HIND-III 
Lane 2 - Ikb DNA ladder 
Lane 3 - uncut VCAM-2 plasmid 
The samples were run against a Ikb DNA ladder and their length was calculated by 
comparing their positions on the gel to the bands o f the DNA ladder.
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13,000 rpm for 15 min, and then drained until the pellet was dry. An appropriate 
amount of ddHaO was added and the sample was incubated in a waterbath at 65°C for 
10 min to dissolve the RNA. The amount of RNA was determined as before. lOpg 
batches of RNA were aliquoted into microcentrifuge tubes containing 250pl ddFl2 0 , 
500jil ethanol and 25p.l 3M sodium acetate (pH 5.2) and stored at -TO^C until required 
for electrophoresis.
In preparation for electrophoresis lOpg of RNA was dissolved in lOpl of ddH2 0  
(65°C for 5 min). 5pi of the following solution was then added ; deionised formamide 
1250pl; 37% formaldehyde 400pl; lOx MOPS 0,2mol/l (0.05mol/l sodium acetate, 
pH7; 0.01 mol/1 Na2EDTA) 250pl. The resulting solution was incubated at 65°C for 10 
min. 2pl of RNA loading dye was added whilst the samples were kept on ice 
constantly. The samples were electrophoresed on an RNA agarose gel.
2.2.14 RNA gels
1.2g of agarose was dissolved in a solution containing 73ml of ddH2 0  and 10ml of lOx 
MOPS. The solution was microwaved for 3min, gently swirling every 20s. 17ml of 
formaldehyde was then added and the solution allowed to cool slightly. The solution 
was poured into a gel plate containing a plastic comb and allowed to set before it was 
submerged in Ix MOPS (20mMol/L) in a G-lOO gel tank. The samples were 
electrophoresed at 60V for 3h.
2.2.15 RNA transfer
RNA was transferred onto Hybond N nylon membranes by blotting in 20xSSC (3moi/L 
NaCl, O.3mol/L NaCit). The RNA was allowed to transfer overnight. The RNA was 
crosslinked onto the nylon membrane using ultra violet radiation (40s at 1 .2 x 1 0  ^
pjoules). The nylon membrane was rinsed for 20s in 5xSSC and small cuts were made 
at the 18S and 28S marker area on the nylon membrane while being viewed on a 
transluminator. The nylon membrane was stored at -20°C in sealed plastic sheeting.
2.2.16 Prehybridisation
250pl of salmon testes DNA (lOOpg/ml) was boiled for 5min and then cooled on ice for 
5 min. This DNA was added to 12ml of the prehybridisation solution which contained 
the following: 2.5ml 10% sodium dodecyl sulphate (SDS), 12.5ml 20xSSC solution, 
5ml Denhardt’s solution, 5g dextran sulphate and 27ml ddH2 0 . 12ml of 
prehybridisation solution was poured into a hybridisation tube. The nylon membrane 
containing the RNA was placed in the tube with the RNA side facing upwards. Air
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bubbles were removed, very gently, with a plastic 10ml pipette. The hybridisation tube 
was placed in the hybridisation incubator at 650C and the nylon membranes were 
prehybridised for a minimum of 4h.
2.2.17 Random priming cDNA probes
The oligolabelling kit contained the reagent mix and Klenow fragment which were used 
in this procedure. The reagent mix was composed of a buffered aqueous solution 
containing deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate (dGTP), 
deoxythymidine triphosphate (dTTP) and random hexadeoxyribonucleotides.
26pl of ddHzO was added to lOpl of a cDNA probe (already aliquoted into 50ng 
batches) and was boiled for 5 min. lOjxl of the reagent mix, 3pl of CTP and Ifxl of 
Klenow fragment were added and the microcentrifuge tube was spun for 5 s to gently 
mix the solutions. The resulting solution was incubated for at least Ih at 37°C.
The radiolabelled probe was then separated from unincorporated 32p CTP on a G- 
50 sephadex column. The radioactive cDNA was boiled for 5 min and placed on ice for 
5 min.
2.2.18 Hybridisation
The radioactive cDNA was injected into the hybridisation tube and the tubes placed in 
the hybridisation incubator at 65®C for approximately 18h.
2.2.19 Washing nylon membranes
The nylon membranes were washed in 15ml of IxSSC (containing 0.5% SDS) for 20 
min at 65®C and then further washed at 0.5xSSC (containing 0.5% SDS). 
Autoradiography was carried out with Fuji X-ray film at -70°C for 24-48h. If necessary 
a further wash in 0. IxSSC was carried out.
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2.3 CELL CULTURE
2.3.1 Human umbilical vein endothelial cell (HUVEC) preparation
All cell culture techniques were carried out in a laminar flow hood.
Umbilical cords were obtained no later than 48h following delivery from 
Glasgow Royal Maternity Hospital. The umbilical cord was cut from the placenta in a 
plastic bag in order to avoid spillage and placed in sterile 0.9% sodium chloride 
solution before being transported to the laboratory. Care was taken not to bend the cord 
during the preparation to avoid smooth muscle cell accumulation. An 180 venflon 
cannula was inserted fully into the vein until the green part of the cannula started to 
enter the vessel. A syringe containing serum free (SF) media (Dulbecco's modification 
of Eagles medium with 4.5g/L dextrose without glutamine with lOOIU/ml penicillin, 
lOOpg/ml streptomycin (P/S), 2 mmol/L glutamine (G) and 2.5pg/ml fungizone (F) 
added) was attached to the cannula. The cord and cannula were clamped using forceps. 
The cord was thoroughly flushed through with SF media until the drained liquid was 
clear with no blood contamination. 0.1% of collagenase (type II) was then added to the 
vessel. The collagenase solution was allowed to run through the vessel for a few 
seconds before the other end of the cord was clamped. Collagenase was added until a 
slight resistance was felt in the syringe. The cord was wrapped in clingfilm and 
incubated at 37°C for 15 min. The collagenase solution from the cord was collected in a 
50ml polypropylene tube. The endothelial cell layer was removed by gently rubbing the 
cord. The cord was then rinsed through with approximately 20ml of SF media. The 
contents of the 50ml tube were pipetted into sterile universal containers and centrifuged 
at 200g for 5 min at 4°C. The supernatant was removed and a further 20ml of SF media 
added. The universal container was tapped slightly to resuspend the cells. This was then 
centrifuged at 200g for 5 min at 4°C. Again the supernatant was removed and 6 ml of 
DMEM, containing 10% FCS, 10% HS, P/S, G and F, was added. After gentle 
trituration the cells were split between two wells of a 6  well cluster plate. The 
endothelial cells were maintained at 37°C in a 5% carbon dioxide (CO2 ) /95% air 
humidified atmosphere. The media was changed on alternate days until the cells were 
confluent. When the cells were confluent (after approximately 2-3 days), they were 
passaged as follows: The medium was removed and 2ml of versene was added to the 
well for 5s, removed and then 1ml of a versene/trypsin (4:1) mix was added to the well. 
The plate was then incubated at 37°C for up to 5 min or until the cells became detached 
from the well bottom (a gentle tap to the bottom of the well aided detachment). 
Medium was added to the cells, which were then spun at 200g for 5 min at 4<^ C to 
obtain the cell pellet. The supernatant was then discarded. The appropriate amount of
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medium was added to the cells which were then triturated to obtain a single cell 
suspension and were then plated out in a 1:3 split ratio onto gelatin coated plates. 
(Plates were previously coated with 1ml of a 2% gelatin solution, incubated at 37°C for 
Ih, rinsed thoroughly with SF media and dried for 2h at 37®C). When setting up 8  well 
Labtek chamber slides with endothelial cells, the wells were treated with gelatin as 
before, and 350|il of the single cell suspension in DMEM were added to the wells.
After the first passage the endothelial cells were maintained in the presence of 
endothelial cell growth supplement at 50jig/ml. The endothelial cells were used up to 
the second passage. Endothelial cells grow to form a cobblestone morphology at 
confluence (see plate 1). The cells were shown to be endothelial cells by positive 
staining for von Willebrand factor (VWF) (see plate 2). Confluent HUVECS were fixed 
in ice cold 50% acetone/methanol (1:1) for 10 min at 4°C. The cells were washed with 
PBS for 5 min and then incubated with rabbit, anti-human, von Willebrand factor 
(diluted 1 in 200 in PBS) for 30 min at 37®C. The cells were then washed with PBS for 
3, 15 min incubations. Next, the cells were incubated with donkey, anti-rabbit Ig, 
fluorescein, for 30 min, at 37^C. This was followed by 2, 15 min washes in PBS. The 
cells were then mounted in Vectashield mounting medium. Control cells were 
incubated as described above but with the first antibody omitted.
2.3.2 Patient sample collection and preparation
2.3.3 Patient Details
The pre-eclamptic pregnancies in each study were defined as having a persistent 
diastolic blood pressure > 90mm Hg, with proteinuria > 0.3mg/24h. All patients were 
normotensive before 20 weeks gestation. Pregnancies complicated by lUGR had 
estimated fetal weight < 5th centile and Doppler ultrasound of the umbilical artery 
demonstrated absent end-diastolic flow velocity. Local birthweight centiles were used.
2.3.4 Blood collection tubes
10ml glass tubes were purchased from LIP Equipment Services (Yorkshire, England). 
The 10 ml disposable plastic tubes were obtained from Sarstedt (Leicester, England).
2.3.5 Plasma preparation
Up to 10ml of blood was added into pre-cooled Sarstedt 10ml tubes containing 1ml of 
3.2% sodium citrate. The blood was spun at l,500g for 15 min at 4°C as soon as 
possible after collection.
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Plate 1. A photograph showing human umbilical vein endothelial cells which were 
prepared as described in section 2.3.1, and grown in a tissue culture flask for 4 days. 
The confluent endothelial cells adopt a typical cobblestone appearance.
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Plate 2. A photograph o f human umbilical vein endothelial cells stained with anti 
human von Willebrand factor and visualised by immunofluorescence, as described in 
section 2.3.1.
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2.3.6 Serum preparation
A maximum of 5ml of blood was added to 10ml glass tubes. The tubes were allowed to 
stand at RT for up to 15 min to clot and then centrifuged at l,500g for 15 min at 4°C.
2.3.7 Plasma and serum storage
After centrifugation the supernatants were removed and aliquoted into 25 Dpi or 500|il 
batches. The microcentrifuge tubes were pre-cooled on dry-ice or taken straight from 
the fridge. Aliquots were frozen immediately in dry-ice until they could be placed in the 
-70^C freezer. The serum was removed with a pasteur pipette and placed into a pre- 
cooled bijoux and then aliquoted. At all times the blood was kept on ice, unless it was 
spinning, or clotting for serum.
2.3.8 Collecting maternal blood
40ml of maternal blood was collected from patients before the onset of labour. 2 x 10ml 
of blood were added to precooled Sarstedt 10ml tubes containing 1ml of 3.2% tri­
sodium citrate to give plasma. 4 x 5ml of blood were added to glass tubes, allowed to 
clot and were processed for serum as previously detailed.
2.3.9 Placentae collection
As soon as the placenta was delivered it was weighed and taken immediately to the 
laboratory. Blood was collected from the cord root and serum and plasma was prepared 
as described above. Surfaces and surgical appliances were sterilised using 70% ethanol. 
While the blood samples were being centrifuged, the placentae samples were collected. 
Approximately Icm^ blocks of placenta were cut using very sharp scissors taking care 
that a full section of placenta was cut each time from the chorionic plate through to the 
basal plate. Each cube of placenta was rinsed 4 times in sterile 0.9% sodium chloride to 
remove as much blood as possible and then placed directly into liquid nitrogen. 
Sections of umbilical cord were also rinsed well and frozen immediately. Sections of 
placenta and cord were placed in 10% buffered formaldehyde for 24h, 50% ethanol for 
8 h, 70% ethanol for up to 24h and then processed in the Pathology Department, 
Glasgow Royal Infirmary using the following protocol. Full sections of placentae were 
cut and placed in green uni-cassettes. The cassette was then placed in the Histokinette 
2 0 0 0  and was then taken through the following solutions; methylated spirits for Ih, 
methylated spirit phenol for Ih 30min, industrial alcohol for Ih 30min, 2h, 2h, and 2h 
30min, industrial alcohol/chloroform (50/50) for Ih, chloroform for Ih 30min, 2h and 
2h, and 2 wax treatments for 2h and 3h 30min. The uni- cassettes were then transferred
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to metal uni-cassettes and embedded using the Tissue Tek 3.
The tissue frozen in liquid nitrogen was placed in pre-cooled storage cryo-tubes 
and stored at -70^C until required for experiments.
2.3.10 Immunocytochemistry
1 0 p.m sections, from the full thickness of placentae frozen in liquid nitrogen, were cut 
on a cryostat and mounted on slides. The slides had previously been soaked in acetone 
for 5 min, 2% silane in acetone for 5 min, washed in water for 30 min and then air 
dried. The sections were then fixed in acetone for 10 min. When carrying out ICC on 
HUVECS on 8 -well chamber slides the cells were first fixed in acetone for 10 min at 
4®C. After air drying for 5 min, PBS was added to the HUVECS which were then 
stored at 4°C until use. 0.5% hydrogen peroxide in methanol was then added to block 
endogenous peroxidase activity. Sections/HUVECS were then washed in TBS buffer 
(5mMol/LTris/Cl, pH 7.4; 0.9% NaCl) and blocked with 20% normal goat serum 
(NGS) for 30 min at RT. Next the sections were incubated overnight at 4°C with 
primaiy cell adhesion molecule antibody diluted in 2% NGS in TBS. The cell adhesion 
molecule antibodies were monoclonal mouse anti-human IgGi subclass (a)PECAM 
(1:500 dilution), (b) E-Selectin (1:250), (c) VCAM-1 (1:500) &(d) ICAM-1 (1:500). 
Negative controls were slides incubated with 2% NGS in TBS or with a mouse 
monoclonal IgGi Aspergillus niger glucose, oxidase an enzyme that is neither present 
nor inducible in mammalian tissue. Sections were next washed in TBS and then 
incubated for Ih at RT with 1:200 biotinylated goat anti-mouse immunoglobulins in 2% 
NGS/5% normal human serum (NHS) in TBS. After washing in TBS, sections were 
incubated for 30 min at RT with 1:400 peroxidase-conjugated streptavidin in TBS then 
washed again in TBS. Finally immunoreactive cell adhesion molecules, which appear 
as a brown end-product, were localised by incubating sections in 1 mg/ml 3,3'- 
diaminobenzidine tetrahydrochloride (DAB) in 0.02% hydrogen peroxide in TBS for 10 
min. The sections were counterstained in Harris haematoxylin.
2.3.11 Mleasuring cell adhesion molecules using ELISA
The cell adhesion molecules VCAM-1, E-Selectin and ICAM-1 were measured by 
enzyme linked immunosorbent assay (ELISA). The protocol provided with each kit was 
followed. This involved the simultaneous reaction of the cell adhesion molecule present 
in the sample or standard to two monoclonal antibodies which were directed against 
different epitopes on the cell adhesion molecule. One antibody was coated onto the 
walls of the microtiter wells and the other was conjugated to the enzyme horseradish 
peroxidase (HRP). Any cell adhesion molecule present formed a bridge between the
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two antibodies. After the unbound material was removed by aspiration and washing, the 
amount of conjugate bound to the well was detected by the reaction with a substrate 
specific for the enzyme which yielded a coloured product proportional to the amount of 
conjugate (and thus cell adhesion molecule in the sample). The coloured product was 
quantified using a spectrophotometer. OD was plotted against concentration of cell 
adhesion molecule in the standard wells, was prepared. By comparing the OD of the 
samples to the standard curve, the concentration of cell adhesion molecule in the 
unknown samples was determined.
2.3.12 Measuring cytokines using ELISA
The cytokines IL-8 , TNFa, IL-lp, GM-CSF, IL-lRA and IL- 6  were measured by 
ELISA. The components required for these procedures were supplied in the Quantikine 
kits. This assay employed the quantitative immunoenzymometric sandwich technique. 
A monoclonal antibody specific for the cytokine was coated onto the microtiter plate 
provided in the kit. Standards with known amounts of the cytokine and the samples 
were pipetted into the wells and any cytokine present was bound by the immobilised 
antibody. Any unbound sample proteins were washed away and an enzyme linked 
polyclonal antibody specific for the cytokine was added to the wells and allowed to 
bind to the cytokine which was bound during the first incubation. After a wash to 
remove any unbound antibody-enzyme reagent, a substrate solution was added to the 
wells and a colour developed in proportion to the amount of cytokine which was bound 
in the initial step. The colour development was stopped and the intensity of the colour 
was measured using a spectrophotometer. A curve was prepared, plotting the optical 
density versus the concentration of the cytokine in the standard wells. By comparing the 
OD of the samples to the standard curve the concentration of the cytokines in the 
unknown samples was determined.
2.3.13 Expression of VCAM-2 and E-Selectin mRNA and protein expression on 
endothelial cells in vitro following treatment with IL-6
HUVECS were isolated as described in section 2.3.1 and were used on the first passage 
at confluence in 6 -well cluster plates.
To assess IL- 6  receptor expression on the cells an anti-human IL- 6  receptor 
antibody was used at 1:1000 dilution. Immunostaining was detected using the ABC 
method with a Vectastain kit according to the manufacturers instructions.
mRNA: The growth medium was replaced with the same medium but with the 
horse serum omitted. This medium contained a range of IL- 6  concentrations (0, 10,
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100, 500, lOOOU/ml) and was incubated with the cells for 4h at 37^C (The stock 
solution of IL- 6  was made up in 0.1% BSA in DMEM). This timepoiiit was chosen 
since pilot experiments showed maximal induction at this time. The cytokine IL-1|3 was 
used at a concentration of 5U/ml as a positive control. A negative control was a well of 
cells which was incubated in the normal growth medium. The RNA was extracted as 
detailed in section 2.2.13. The VCAM-2 and E-Selectin mRNA were assessed by 
Northern blotting using a 1.9kb VCAM-2 cDNA and 1.2kb E-Selectin cDNA 
respectively.
ICC: The growth medium was replaced with the same medium as detailed for 
mRNA. The endothelial cells were treated with 500p.l/ml IL- 6  for 0, 4, 8 , 24h. At the 
end of the incubation, the cells were fixed in acetone and stained using the peroxidase 
labelled streptavidin method (section 2.3.10). Again the primary antibody was the 
monoclonal mouse antibody human IgGi subclass VCAM-1 (1:500) and E-Selectin 
(1:250). The negative controls were cells incubated with mouse monoclonal IgGi Anti 
aspergillus niger glucose oxidase (section 2.3.10).
2.4 Statistics
The values for circulating concentrations of cell adhesion molecules were analysed 
using the Students f-test.
The bands on the autoradiographs showing the cell adhesion molecule expression 
in placentae were quantified with a scanning densitometer and an arbitrary densitometry 
unit was obtained for each band. The mean and SE arbitrary densitometry units were 
calculated for each cell adhesion molecule and compared using ANOVA.
The chi squared test was used to analyse the data for the intensity of staining of 
cell adhesion molecule expression on placenta sections.
The circulating cytokine concentrations were compared using the Mann-Whitney 
U test, whilst the clinical characteristics of the patients were compared using the 
unpaired Student t -test.
The chi squared test was used to analyse the densitometry units obtained for the 
bands on the autoradiograph from the experiments involving the treatment of HUVECs 
with IL-6 .
CHAPTER THREE 
RESULTS
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3 .1  Circulating concentrations of cell adhesion molecules in normal 
and pre eclamptic pregnancies
Circulating concentrations of cell adhesion molecules are thought to be indicative of 
endothelial expression and also endothelial damage. Increased expression of cell adhesion 
molecules is also thought to be associated with leukocyte activation (Harlan and Liu, 
1992). Soluble forms of cell adhesion molecules are detectable in normal serum and 
plasma.
The objective of this study was to measure soluble cell adhesion molecule 
expression in serum and plasma from normal pregnant women and in women with pre­
eclampsia to determine whether circulating cell adhesion molecules, indicating cell 
adhesion molecule expression on the endothelium, might reflect a feature of endothelial 
damage in pre-eclampsia and so contribute to neutrophil activation.
3 .1 .1  Patient details
Sixteen women with pre-eclampsia and 18 women with uncomplicated pregnancies were 
studied. None of the women had any evidence of urinary tract infection or 
chorioamnionitis and none were close to labour at the time of sampling. Venous blood 
samples were obtained from the patients and serum was prepared as described in 
methods. The patients were matched for maternal age and gestational age at the time of 
sampling (Table 1).
3 .1 .2  Cell adhesion molecules serum results
The cell adhesion molecules VCAM-1, E-Selectin and ICAM-1 were measured in 
maternal serum by ELISA. The pre-eclamptic patients had significantly higher 
concentrations of the cell adhesion molecule VCAM-1 compared to the control group 
(Table 2). However there were no significant differences in the adhesion molecules 
ICAM-1 or E-Selectin in pre-eclampsia compaied to normal pregnancy (Table 2).
3 .1 .3  Follow up study
Susequent to this work, a study by Pickling et al (1995) suggested that E-Selectin was 
significantly increased in patients with pre-eclampsia compared to normal pregnant and 
non-pregnant patients. We therefore performed a follow up study to determine whether 
plasma and serum concentrations of E-Selectin were similar and could the differences in 
results be explained by whether serum or plasma was used. By the time this follow up
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study was performed we had increased the number of blood samples collected for our 
study groups.
3 .1 .4  Patient details
The number of patients in this study were increased to 32 pre-eclamptics and 30 normal 
pregnant women. Venous blood samples were obtained from all patients and plasma was 
prepared as described in the methods chapter.
3 .1 .5  Cell adhesion molecule plasma results
E-Selectin concentrations were significantly higher in the plasma samples from women 
with pre-eclampsia compared to the normal pregnant controls (Table 3). Values for E- 
selectin were found to be lower in plasma when compared with the serum samples. 
When we analysed the E-Selectin concentrations in serum from the women recruited in 
the original study (16 pre-eclamptics and 18 normal pregnant women) there were no 
significant differences between the two groups.
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Variable Normal Pre-eclampsia
n = 18 n = 16
Age (years) 23 ± 3 26 ± 6
Gestational age at sampling (weeks) 31 ±3 33 + 4
Platelet count ( x 10^ /1) n/a 220 ± 57
Plasma urate (mmol/1) n/a 0.36 + 0.06
Table 1. Characteristics of primigravid women with and without pre-eclampsia. 
Data are shown as mean + SD values.
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Concentration of cell Normal Pre-eclampsia
adhesion molecule (ng/ml) n = 18 n = 16
VCAM-1 560.2 ±  47.9 841.9 ±49.7*
ICAM-1 187.3 ±  15.8 148.8 ± 11.9
E-Selectin 45.8 ±4.6 49.8 ± 7.2
*P<0.001
Table 2. Cell adhesion molecule concentrations in serum from women with and without 
pre-eclampsia
Mean (SE) values were compared by Student's t test.
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Concentration of cell Normal Pre-eclampsia
adhesion molecule (ng/ml) n = 30 n= 32
E-Selectin 29.11 + 2.84 41.90 4- 2.76
Table 3. E-Selectin concentrations in plasma samples from women with and without pre­
eclampsia. Data is shown as mean ± SE.
P <.005 compared to normal pregnant group.
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3 .2  Cell adhesion molecule mRNA and protein expression in placentae 
from normal pregnant patients compared to patients with pre­
eclampsia or lUGR
Our work leading up to this study had shown that VCAM-1 and E-Selectin were 
increased in the maternal circulation of women with pre-eclampsia. Although previous 
data had suggested that neutrophil activaton was confined to the maternal circulation in 
pre-eclampsia we carried out experiments to determine if there were altered cell adhesion 
molecules on endothelial cells, trophoblasts or decidua in placenta from women with pre­
eclampsia. Such expression on trophoblast or decidua could explain the neutrophil 
activation, placental damage and increased neutrophil content of decidua in pre-eclampsia.
3 .2 .1  Patient details
Placentae from 15 pregnancies complicated by pre-eelampsia (gestation at deliveiy 34.3 ± 
0.85 SE weeks), 10 pregnancies complicated by pre-eclampsia and lUGR (gestation at 
delivery 32.97 ± 0.72 SE weeks) and 7 pregnancies complicated by lUGR (gestation at 
delivery 31,18 ± 2.9 SE weeks) were matched for gestation with normal placentae from 
pregnancies delivered early for reasons such as placenta praevia, previous caesarean 
section and breech presentation (gestation at delivery 34.6 ± 0.86 SE weeks). All the 
patients were matched for maternal age, parity and smoking habit. None of the women in 
the study had evidence of urinary tract infection or chorioamnionitis.
3 .2 .2  mRNA expression of cell adhesion molecules in placentae
Northern analysis of cell adhesion molecule mRNA expression in normal placentae is 
shown in plate 3. PEC AM mRNA was the most abundant species present. Numerous 
species of PEC AM were detectable, the two major transcripts being approximately 3.5 
and 3.7 kb. ICAM -1 cDNA was expressed as two bands, one at 3.3kb and another 
weaker band at 2.4kb. The expression of ICAM-2 was higher than ICAM-1, the cDNA 
hybridising to a 1.4kb mRNA transcript. Both the ICAM-1 bands and the ICAM-2 band 
have previously been reported to be present in cultured endothelial cells by Staunton, 
Dustin and Springer (1989). The 1.2kb E-Selectin and 1.9kb YCAM-2 mRNA were both 
undetectable by northern blotting in placentae from all noimal placentae. When comparing 
the expression of all the cell adhesion molecules mRNAs in placentae from pregnancies 
complicated by pre-eclampsia, lUGR or pre-eclampsia and lUGR to placenta from 
normal pregnancies, there were no significant differences (Tahle 4).
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3 .2 .3  Cell adhesion molecule protein expression in placentae
Strong immunostaining for PECAM was apparent throughout the vascular tree in normal 
placentae. Strong staining was localized to the endothelium of stem villi (plate 4A), the 
intermediate villi (plate 4B) and the terminal villi (plate 4B). PECAM was also found in 
the endothelium of the decidual vessels. Staining was not apparent in the fetal 
membranes. Like PECAM, ICAM-1 staining was scattered throughout the vascular tree, 
again in the endothelium of the stem villi, intermediate villi and terminal villi (plate 4C 
and4D). Faint staining occurred in the stroma, perhaps indicating macrophage staining 
(plate 4D). Otherwise there was no extravascular expression in trophoblast or decidua. 
The endothelium of all the vessels were negative for both VCAM-1 and E-selectin 
immunostaining(plate 4E and 4F respectively). There were no significant staining 
differences in the immunostaining for PECAM, ICAM-1, VC AM or E-Selectin in 
placentae complicated by pre-eclampsia or lUGR (Table 5).
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PECAM ICAM-1
k r .
ICAM-2 VCAM-1 E-Selcctin
28S
18S
Plate 3. Northern analysis o f cell adhesion molecule expression in placentae. RNA was 
extracted from the placentae, run on agarose gels and blotted onto nylon membranes. The 
membranes were then hybridised with a cDNA probe as described in sections 2.2.13 - 
2.2.19, washed to a final stringency o f 0.5 x SSC at 65®C. Autoradiography was 
performed with Fuji x-ray film overnight at -TO^C. The 28S and 18S rRNA bands are 
marked by the arrows.
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Control
(n = 10) 
Densitometiy 
units
Pre-eclampsia
(n = 15) 
Densitometiy 
units
Pre-eclampsia 
+ IUGR 
(n = 10) 
Densitometiy 
units
lUGR
(n -7 )
Densitometry
units
PECAM 9.7 ± 1.3 9.3 ± 0.97 9.1 ± 1.1 8.9 ± 0.5
ICAM-2 8.5 ±0.8 8.8 ±0.8 8.3 ± 0.5 8.7 ± 0.7
ICAM-1 (3.3kb) 2.2 ± 0.4 2.4 ±0 .4 2.2 ± 0.5 2.6 ± 0.6
ICAM-1 (2.3kb) 1.5 ± 0.2 1.5 ±0.2 2.0 ± 0.5 1.8 ±0 .4
VCAM 0 0 0 0
E-Selectin 0 0 0 0
Table 4. Scanning densitometer analysis of cell adhesion molecule expression in 
placentae.
Bands on the autoradiographs were quantified with a scanning densitometer and an 
arbitrary densitometry unit was obtained for each band. The mean and SE arbitrary 
densitometry units were calculated for each cell adhesion molecule and compared using 
ANOVA.
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Plate 4. Photomicrographs o f the cell adhesion molecule immunostaining in the vascular 
tree o f a placenta from a normal pregnancy. PECAM staining was localized to the 
endothelium of the stem villi (S V )[A ], the intermediate villi (IV)[B] and the terminal villi 
(TV)[B]. Like PECAM, ICAM-1 was scattered throughout the vascular tree, in the 
endothelium o f the stem villi, intermediate villi and terminal villi (C and D). ICAM-1 
staining also occurred in the stroma (D). The endothelium o f all the vessels was negative 
for both VCAM-1 and E-Selectin (E and F respectively).
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Diagnosis Normal Pre-eclampsia Pre-eclampsia 
+ IUGR
lUGR
No. samples 10 15 10 7
No. fields scored 20 20 20 20
per section
Endothelial
staining
PECAM + + + +
ICAM + + +
E-Selectin “ " - -
VCAM - - - -
Stromal staining
PECAM - - - -
ICAM + + + +
E-Selectin - - - -
VCAM - - - -
Mean intensity
endothelial staining
PECAM +++ +++ +++ +++
ICAM +++ ++-+- +++ H-++
Mean intensity of
stromal staining
ICAM + + + +
Table 5. Immunolocalization of cell adhesion molecules in placentae.
Twenty fields were examined for each section by an investigator blinded to the tissue 
identity and scored for location of staining of the endothelium or stroma (+ or -) and for 
the intensity of the staining (+, ++ or +++). Statistical analysis was performed using the 
test. The mean scores for each group are shown.
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3 .3  Circulatory cytokines in normal pregnancy and pre-eclampsia
Our previous studies, including the demonstration of increased cell adhesion molecules, 
suggested that neutrophil activation occurs in pre-eclampsia. Leukocytes (including 
neutrophils) are stimulated and inhibited by a lai'ge number of agents, including cytokines 
which may act directly on neutrophils or indirectly via stimulation of cell adhesion 
molecules. In this study, we aimed to determine whether there was evidence of increased 
circulating concentrations of candidate cytokines (i.e. those known to activate 
neutrophils) in plasma from women with pre-eclampsia.
3 .3 .1  Patient details
Twenty primigravidae with pre-eclampsia and 15 primigravidae with uncomplicated 
pregnancies were studied. None of the women had any evidence of urinary tract infection 
or chorioamnionitis and none were close to labour at the time of sampling. Venous blood 
samples were obtained from all patients and plasma was prepared as described before. 
The patients were matched for gestational age. Maternal age, gestation at the time of 
sampling, gestation at delivery, birthweight and placental weight were compared using 
the unpaired Student t test (Table 6). There were no significant differences between the 
groups studied in terms of maternal age, parity and gestational age at the time of blood 
sampling. However, the mean gestational age at delivery, the mean birthweight and the 
mean placental weight were all significantly lower in the pre-eclamptic group compaied to 
the normal group.
3 .3 .2  Cytokine results
The concentration of the cytokines IL-6, II-Ira, TNFa, IL-8, GM-CSF and IL-1(3 in 
plasma are shown in table 7. Interleukin-6 concentrations were significantly higher in the 
patients with pre-eclampsia compared to the normal patients (P < 0.01), as were the 
concentrations of IL-lra (P < 0.01). For the other cytokines measured there were no 
significant differences between pre-eclamptics compared to normal patients. The 
concentration of cytokines detected in all the samples was above the lower limits of 
detection of the assays.
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Vai'iable Normal Pre-eclampsia
Number of primigravidae 15 20
Age (years) 24.6 ± 4.5 29.5 ± 7.4
Gestational age at sampling (weeks) 32.6 ± 3.7 33.05 ± 3.7
Gestational age at delivery (weeks) 39.2 ± 2.2 33.3 ± 3.5*
Placental weight (g) 731.83 ± 170.51 427.36 ± 173.45*
Birth weight (kg) 3.51 ±0.6 1.83 ±0.87*
Platelet count (xlO^/L) - 241 ± 66
Plasma urate (mmol/L) “ 0.36 ± 0.07
Number < 5th percentile 0 8
Table 6. Clinical characteristics of women with and without pre-eclampsia.
Data are presented as mean ± standard deviation. * P < .0001 compared with the normal 
pregnant group (unpaired Student r-test).
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Cytokine Cytokine levels (pg/ml) 
in control subjects 
n = 15
Cytokine levels (pg/ml) 
in pre-eclamptic subjects 
n = 20
IL-6 2.06 (1.44 - 3.63) 2.56 (1.48 - 5.06)*
11-Ira 142.00 (36.84 - 603.10) 251.85 (96.25 - 806.50)*
TNFa 11.96 (9.6 - 16.39) 14.09 (8.33 - 41.06)
11-8 44.46 (34.90 - 67.86) 50.52 (37.71-60.28)
GM-CSF 121.3 (90.67-167.6) 125.8 (86.12 - 183.2)
IL-lp 2.01 (1.64 - 2.62) 2.08 (1.52 - 3.19)
Table 7. Cytokine concentrations in plasma from women with and without pre­
eclampsia.
Data are presented as mean cytokine concentration (range).* P < .01 compared with the 
normal pregnant group (Mann-Whitney U test).
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3 .4  Expression of VCAM protein and mRNA on HUVECS in vitro 
following treatment with IL-6.
Our previous experiments have shown that both IL-6 and VCAM-1 and E-Selectin are 
increased in pre-eclampsia. These data raised the possibility that IL-6 may, at least in 
part, be responsible for the increased expression of cell adhesion molecules seen in this 
condition. The aim of the next set of experiments was to determine whether IL-6 had an 
effect on the expression of the cell adhesion molecules VCAM and E-Selectin on human 
umbilical vein endothelial cells.
Firstly we established that endothelial cells expressed IL-6 receptors. 
Immunocytochemistry was carried out in cultured endothelial cells with an IL-6 receptor 
antibody. To confirm that the results obtained were not due to the in vitro conditions, 
parallel experiments were carried out on cryosections of normal placenta. Plate 5 shows 
that both endothelial cells in vitro and endothelial cells in the vessels of the placenta 
stained positively for the IL-6 receptor antibody.
3 . 4 . 1  Protein VCAM-1 results
The VCAM-1 protein was almost undetectable on untreated HUVECS. Following 
incubation with 500U/ml IL-6 (which produced maximum effect), there was a significant 
increase in VCAM-1 immunostaining at 4h which remained elevated at 8h and declined 
by 24h. By 24h, the VCAM-1 protein expression was comparable to that at 4h (plate 6). 
No staining was detected on the negative controls. The same results were achieved in 3 
separate experiments with 3 different cell cultures.
3 . 4 . 2  mRNA VC AM-2 results
Unstimulated HUVECS expressed little or no VCAM-2 mRNA. Following treatment 
with lOU/ml, lOOU/ml, 500U/ml, and lOOOU/ml IL-6 for 4h, there was a dose 
dependent increase in VCAM-2 mRNA expression which reached maximal levels at 
lOOOU/ml (plate 7). 3 separate experiments showed the same results.
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3.5  Expression of E-Selectin protein and mRNA on HUVECS in vitro 
following treatment with IL-6
3 .5 .1  Protein E-Selectin results
The E-Selectin protein was undetectable on untreated HUVECS. Following incubation 
with 500U/ml IL-6, there was a significant increase in E-Selectin protein expression at 4h 
which remained elevated at 8h and declined by 24h, with maximum expression at 4-8h 
(plate 8). A maximum effect was found with lOOOU/ml IL-6. No staining was detected 
on the negative controls. The same results were achieved on 3 separate occasions.
3 .5 .2  mRNA E-Selectin results
E-Selectin mRNA expression was undetected on untreated HUVECS. After treatment 
with lOU/ml, lOOU/ml, 500U/ml and 1000 U/ml IL-6 for 4h, there was a dose 
dependant increase in E-Selectin mRNA expression, which reached maximal levels at 
500U/ml (plate 9). 3 separate experiments showed the same results.
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Plate 5. Endothelial cells  express IL-6 receptors both in v ivo  and in vitro . 
Im m u n ocytoch em istry  w as perform ed as described  in sectio n  2 .3 .1 3 .  
Immunolocalization o f IL-6 receptor protein on HUVECS in vitro is shown in plate (b) 
and on a term human placenta cryosection in plate (d). Plates (a) and (c) show in vitro 
and in vivo immunostaining respectively when the primary antibody was omitted.
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Plate 6. Immunocytochemistry was performed as described in section 2.3.13. These 
photographs show VCAM -1 immunostaining on HUVECS after incubation with 
500U/m l IL-6 at time 0 (a), 4h (b), 8h (c), and 24h (d).
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(a)
(b)
10 100 500 1000 U/ml
(c)
IL-6 U/ml 0 10 100 500 1000
Densitometry
units
0* 0.85 ±  0.2*^ 3.4 ± 0 . 5 # 6.3 ±  1.2$ 8.5 ±  1.1
* P < 0.05
# P < 0.05 
$ P <  0.05
Plate 7. A photograph of a gel showing even loading of RNA (lOpg/lane) and intact 28S 
andlSS rRNA bands(a). A representative autoradiograph showing VCAM -2 m RNA  
expression in HUVECS after incubation with lOU/ml, lOOU/ml, 500U/ml and lOOOU/ml 
IL-6 for 4h(b). After incubation with IL-6 the RNA was extracted from the cells, run on 
an agarose gel and blotted onto a nylon membrane. The membrane was hybridised with a 
1.9kb VCAM -2 cDN A probe as described in section 2.2.17 and then washed to a final 
stringency of 0.1 x SSC at 65®C. The autoradiograph was exposed to Fuji x-ray film for 
3 days at -70^C. Bands on the autoradiographs were quantified with a scanning 
densitometer and an arbitrary densitometry unit was obtained for each band (c). The mean 
and SD densitometry units are shown for 3 separate experiments.
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Plate 8. Immunocytochemistry was performed as described in section 2.2.13. These 
photographs show E-selectin immunostaining on HUVECS after incubation with 
500U/ml IL-6 at time 0 (a), 4h (b), 8h (c) and 24h (d).
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(a)
(b)
0 10 100 500 1000 U/ml
c.
11-6 U/ml 0 10 100 500 1000
Densitometry
units
0* 4.1 ± 0 .1 * # 8.5 ±  0.7# 9.1 ±  1.1 9.7 ±  0.5
* P < 0.05
# P < 0.05
Plate 9. A photograph of a gel showing even loading of RNA ( lOpg/lane) and intact 28S 
andlSS rRNA bands (a). A representative autoradiograph showing E-Selectin mRNA  
expression in HUVECS after incubation with lOU/ml, lOOU/ml, 500U/ml andlOOOU/ml 
IL-6 for 4h (b). After incubation with IL-6 the RNA was extracted from the cells, run on 
an agarose gel and blotted onto a nylon membrane. The membrane was hybridised with a 
1.2kb E-Selectin cDN A probe as described in section 2.2.17 and then washed to a final 
stringency of 0.1 x SSC at 65^C. The autoradiograph was exposed to Fuji x-ray film for 
3 days at -70®C. Bands on the autoradiographs were quantified with a scanning 
densitometer and an arbitrary densitometry unit was obtained for each band (c). The mean 
and SD densitometry units are shown for 3 separate experiments.
CHAPTER FOUR 
DISCUSSION
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4 .1  Introduction to discussion
Endothelial damage and dysfunction are common to all the pathophysiological features of 
pre-eclampsia. Increased circulating concentrations of cell adhesion molecules and 
cytokines may indicate leucocyte-endothelial attachment and activation resulting in 
damage to the endothelium.
4 .2  Cell adhesion molecules in pre-eclampsia
4 .2 .1  VCAM
VCAM-1 is a 90-110kDa glycoprotein expressed on the surface of activated endothelium 
and on a variety of other cell types, including tissue macrophages and bone marrow 
fibroblasts. The maternal serum, from the women with pre-eclampsia we studied, had 
significantly higher levels of soluble VCAM-1 compared to the control group. This may 
reflect increased expression of VCAM on the endothelium and perhaps represents a 
possible mechanism by which leucocytes are attached to the endothelium, where they 
contribute to the endothelial dysfunction seen in pre-eclampsia (Lyall et al. 1994). 
VCAM-1 may be cleaved or shed from the cell surface but the mechanism by which this 
occurs is not known. VCAM-1 therefore may be upregulated by a mechanism which is 
triggered by an effective inflammatory response in the maternal circulation in pre­
eclampsia. No evidence of VCAM-2 mRNA or protein expression was found in the 
placentae of women with pre-eclampsia, lUGR or control pregnant women. This 
suggests that increased VCAM expression may be confined to the maternal circulation in 
pre-eclampsia. Feng et al (1996) found higher levels of soluble VCAM-1 in cord blood 
compared to maternal blood in uncomplicated term gestations in labour. This may be a 
consequence of the process of labour which is itself an inflammatory process. This might 
also be the mode of leucocyte activation described by Greer et al (1991a).
4 .2 .2  ICAM-1 and ICAM-2
ICAM-1 and ICAM-2 bind the leucocyte beta2 integrin, LFA-1, via the immunoglobulin 
domains 1 and 2. ICAM-2 consists only of immunoglobulin domains 1 and 2, so closer 
cell-cell contact is required for ICAM-2 binding whilst ICAM-1 also binds to Mac-1 via 
domain 3 (another beta2 integrin on leucocytes) (Zimmerman et al. 1992). In our study 
there were no significant differences in the serum levels of soluble ICAM-1 between 
women with pre-eclampsia and normal pregnant women, which agrees with a study by 
Fickling et al (1995). In the placenta, we found weak expression of ICAM-1 mRNA in 
two bands, whilst a stronger ICAM-2 mRNA band was expressed. Since ICAM-1 is
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induced on endothelial cells by certain cytokines, and ICAM-2 is expressed constitiitively 
on endothelial cells, monocytes and lymphocytes (Staunton et al. 1989) and is not 
affected by cytokines, we would expect the expression of ICAM-2 to be greater. ICAM-2 
expression was greater than ICAM-1 expression in each of the groups we studied. 
ICAM-2 may play a role in normal lymphocyte recirculation so strong expression would 
be expected in normal placentae. ICAM-1 staining was found in the endothelium of the 
stem villi, intermediate villi and terminal villi and also in the stroma (Lyall et al. 1995a). 
Labarrerre and Faulk (1994) found ICAM-1 expressed on endovascular cytotrophoblasts 
in abnormal pregnancies (including women with pre-eclampsia, lUGR and women with a 
history of secondary recurrent spontaneous abortion) but not in placentae from normal 
pregnancies. ICAM-1 and ICAM-2 have established roles in endothelium/neutrophil and 
endothelium/platelet interactions. Neutrophils and platelets are activated in pre-eclampsia 
but there was no increase in expression of these cell adhesion molecules in the maternal 
serum or in the placenta from patients with pre-eclampsia. Thus ICAM-1 and ICAM-2 
are unlikely to be significant factors in the neutrophil activation and endothelial 
dysfunction of pre-eclampsia.
4 .2 .3  E-Selectin
E-Selectin, a member of the Selectin family of adhesion molecules, has a molecular 
weight of 95-115kDa. E-Selectin expression is protein synthesis-dependent, peaking 
after 4-6 hours stimulation by the cytokines IL-1 or TNFa and declining to basal levels 
by 24 hours (Needham et al. 1991). In our study, there were no significant differences in 
the serum levels of soluble E-Selectin between women with pre-eclampsia and normal 
pregnant women. However, our follow-up study, with an increase in patient numbers 
found that soluble E-Selectin plasma concentrations were significantly higher in women 
with pre-eclampsia. The differences in E-Selectin concentrations between plasma and 
serum may be due to the semm containing no coagulant, which could be important for the 
expression of E-Selectin.
We found no evidence of E-Selectin mRNA or protein expression in the placentae 
studied. Although we have shown an increase in soluble E-Selectin in the maternal 
circulation in pre-eclampsia there was no increase in this cell adhesion molecule in the 
placentae from patients with pre-eclampsia or lUGR. E-Selectin may therefore play a role 
in the recruitment and subsequent activation of neutrophils in the maternal circulation in 
pre-eclampsia with expression in the maternal circulation rather than in the placenta. 
Austgulen et al (1997) found that maternal plasma levels of soluble ICAM-1, soluble 
VCAM-1 and soluble E-Selectin were increased in pre-eclamptic pregnancies. The 
changes in the soluble cell adhesion molecule concentrations of VCAM-1 and E-Selectin 
in our study support the idea that changes in endothelial cell function aie important in the
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aetiology of pre-eclampsia.
4 .2 .4  PECAM
PEC AM is a 120-130KDa glycoprotein expressed in large amounts on endothelial cells at 
intercellular junctions, and on T cells. Recently PECAM has been shown to play an 
important role in the extravasation of natural killer cells into sites of inflammation 
(Berman et ah 1996). It is expressed in smaller amounts on platelets and most other 
leucocytes, including monocytes and neutrophils (Vaporciyan et al. 1993) and is required 
for transendothelial migration of leucocytes through intercellular junctions of vascular 
endothelial cells (Muller et al. 1993). In this study, numerous species of PECAM mRNA 
were detected and PECAM protein expression was found constitutively on the 
endothelium of the stem villi, intermediate villi and terminal villi as well as the 
endothelium of the decidual vessels. PECAM was not seen in the fetal membranes. 
PECAM has an established role in endothelium/neutrophil and endothelium/platelet 
interactions, but there was no evidence of increased expression of PECAM in the 
placentae from patients with pre-eclampsia or lUGR. Because PECAM was found in 
abundance in contiol placentae, it is possible that the immunocytochemistry and Northern 
blotting methods were not sensitive enough to show a difference between control and 
pre-eclamptic placentae. Measuring each species of PECAM mRNA may have shown a 
difference between the two groups. However, the abundant expression in normal 
pregnancy suggests that PECAM expression is not a major factor in the pre-eclamptic 
process.
Ruck et al (1994) investigated first trimester human decidua, from normal pregnant 
women, for cell adhesion molecules involved in the interactions between the various 
maternal and fetal cell populations. ICAM-1 and VCAM-1 staining was observed in the 
stromal cells. Both PECAM and ICAM-1 were observed on the endothelium of a large 
number of blood vessels whilst VCAM-1 stained positive on the endothelium of 
arterioles, venules and a few capillaries. Weak E-Selectin staining was seen in a few 
aiterioles and venules on the endothelium. In our study we found PECAM and ICAM-1 
on the endothelium of decidual vessels but found no VCAM-1 or E-Selectin staining in 
the trophoblast or stromal tissue. Ruck et al (1994) found positive staining for both E- 
Selectin and VCAM-1 in first trimester decidua whilst we found no VCAM-1 or E- 
Selectin staining in term placentae suggesting that there may be a mechanism that 
downregulates these cell adhesion molecules in the later stages of normal pregnancy.
There were no differences in cell adhesion molecule immunostaining or mRNA 
expression in placentae from pregnancies complicated by pre-eclampsia or lUGR. These 
results suggest that cell adhesion molecules have a normal physiological role in the fetal 
circulation which does not alter in pregnancies complicated by pre-eclampsia or lUGR.
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4 .3  Cytokines
Our previous work has shown that the cell adhesion molecule VCAM-1 is elevated in the 
serum of women with pre-eclampsia. Increased expression of adhesion molecules by the 
endothelium could be responsible for the neutrophil activation which occurs in pre­
eclampsia. Cytokines could be responsible for features of endothelial dysfunction, 
including neutrophil activation and certain cytokines stimulate endothelial cells from their 
normal anticoagulant state to a procoagulant state with increased adhesiveness for 
leucocytes and platelets to the endothelium. Cytokines contribute to the maintenance of 
normal pregnancy. TNFa and GM-CSF probably influence trophoblast growth and 
differentiation in early pregnancy since their receptors are present on trophoblasts (King 
et al. 1995b Burrows et al (1994) suggested that during implantation the vascular 
invasion by trophoblasts was regulated by the expression of the appropriate adhesion 
molecules, which permitted interaction between endovascular trophoblast and decidual 
endothelial cells. GaiciaLloret etal (1994) found that placental fibroblasts underlying the 
trophoblast epithelium produced GM-CSF and CSF-1 and suggested that a network of 
cytokines played a significant role in the morphological and functional development of the 
human placenta. We know that in pre-eclampsia the primaiy invasion of the spiral arteries 
in the uteroplacental bed is impaired. Cytokines are involved in cytotrophoblast 
differentiation in normal pregnancy so perhaps a disturbance in the cytokine concentiation 
has a detrimental effect on the differentiation process, resulting in the development of 
pre-eclampsia. We found significantly higher concentrations of the cytokines IL-6 and 
XL-Ira in patients with pre-eclampsia compared to normal pregnant patients. There were 
no significant differences in the concentrations of TNF-a, IL-8, GM-CSF and XL-Ip 
between the two groups.
4 .3 .1  XL-1/XL-Ira
XL-1 is a polypeptide produced during infection, injury or immunologic challenge. There 
are two molecular forms XL-la and XL-Ip and despite only a 26% amino acid homology 
both forms induce a wide variety of biological changes (Dinarello & Savage, 1989). 
Acute atherosis occurs in the spiral ai'teries of the placental bed in pre-eclampsia, which 
may be a result of XL-1 taigetting endothelial cells and contributing to the development of 
these atherosclerotic lesions (Dinarello et al. 1993). The potent effects of XL-la and XL- 
Ip aie modulated by the naturally occurring inhibitor XL-Ira (Dinarello et al. 1991b). XL- 
Ira has been cloned, it is produced in recombinant organisms, and is thought to play an 
important role in the normal physiological or pathophysiological states by functioning as 
a natural XL-1 receptor antagonist (Arend et al. 1990). Inhibition of the cleavage step is
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required to generate an active form of IL-1 is a potential mechanism for reducing IL-1 
activity (Cerretti et al. 1992). IL-Ira competes with the binding of IL-1 to its cell surface 
receptors (Seckinger et al. 1987) but does not result in signal transduction. A 50% 
inhibition of IL-1 induced biological responses requires amounts of IL-lra up to 100 fold 
in excess of the amounts of IL-1 a  or IL-1 P present. IL-lra may be potentially useful as a 
therapeutic agent for the treatment of IL-1 mediated diseases in humans (Eisenberg et al. 
1990). IL-lra administration to animals significantly reduces the severity of disease. IL- 
lra can block endotoxin-induced IL-8 production which may be a major component of 
the anti-inflammatory property of IL-lra (Porat et ah 1992). The increase in IL-lra, in the 
present study may be due to the upregulation of IL-lra to reduce the inflammation, 
mediated by IL-1, in the peripheral circulation in pre-eclampsia. IL-lra may be blocking 
the activity of IL-1. As IL-lra is approximately 100 fold less effective at binding to IL-1 
receptor, substantially higher quantities are required to compete with the small 
concentration of IL-1. As IL-1 has a local effect, and we measured systemic 
concentrations, the difference in concentration may be too low to be picked up by the 
assay. IL-lra may therefore act as a surrogate measure of IL-ip as well as being an 
important factor in antagonising the effect of IL-1.
4 .3 .2  EL-6/TNFa
IL-6 may be an important regulator of the host defence response and its production by 
endothelial cells may contribute to the pathogenesis of various inflammatory and 
immunologic diseases. Gunn et al (1996) found that in normal pregnancy the 
concentration of IL-6 in amniotic fluid and fetal membranes increased after the onset of 
labour suggesting that during labour the fetal membranes are the main source of IL-6. 
Decreased levels of IL-6 were found in the amniotic fluid of patients with pre-eclampsia 
suggesting a role for IL-6 in the pathophysiology of pre-eclampsia (Silver et ah 1993). 
Increased circulating concentrations of IL-6 may be a consequence of increased TNF 
production (Jirik et al. 1989). IL-6 is involved in the modulation of TNF production 
(Akira et al. 1993) and stimulation of TNF-R shedding (Aderka et al. 1993). There are 
two specific receptors for TNF which have molecular weights of 55kDa and 75kDa, 
called p55TNF-R and p75TNF-R (Tartaglia and Goeddel, 1992). By binding circulating 
TNF, the soluble receptors are thought to prevent target cell activation and provide a 
protective mechanism against TNF overproduction (Aderka et al. 1993). In vivo soluble 
TNF-R may play a role in modulating the activity of TNF, since each receptor is shed as 
a soluble protein that specifically binds to TNF, inhibiting its activity (Van Zee et al. 
1992). The source of the circulating p55TNF-R and p75TNF-R is not known but Porteau 
and Nathan (1990) suggested that the receptors may be derived from activated 
neutrophils. This would agree with reports that activated neutrophils occur in pre­
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eclampsia, resulting in increased TNF-R concentrations in the disease state. There is 
increased expression of TNFa mRNA in leucocytes from patients with pre-eclampsia 
which may be associated with the TNF 1 allele whose frequency is markedly increased in 
pre-eclamptic patients. A disturbance of TNFa may therefore contribute to the endothelial 
damage seen in pre-eclampsia (Chen et al. 1996). Wang and Walsh (1996b) found 
increased concentrations of TNFa protein and TNFa mRNA in pre-eclamptic placentae 
compared to controls. They suggested that the increase of TNFa was associated with 
increased lipid peroxidation since TNFa induces oxygen free radicals which are involved 
in the initiation of lipid peroxidation. Meekins et al (1994) suggested that TNFa does not 
contribute to the initiation of endothelial cell activation that may be associated with the 
development of pre-eclampsia but may arise as a consequence of the pathological 
processes of pre-eclampsia. Meekins (1995) confirmed this hypothesis by showing that 
TN Fa was increased in women with pre-eclampsia, only after the disease had been 
diagnosed. TNFa was not increased in patients who were sampled before they developed 
pre-eclampsia compared to normal pregnant women. Kupferminc et al (1996) found 
increased levels of soluble TNF-R in amniotic fluid and maternal plasma samples from 
patients with severe pre-eclampsia which returned to normal control levels after 24 hours 
post paitum. They found increased IL-6 concentrations in maternal plasma before the 
onset of labour, again providing a link between increased levels of TNF and IL-6, both 
contributing to endothelial cell dysfunction. Opsjon et al (1995) found an increase in 
p55TNF-R in the maternal semm from patients with pre-eclampsia before the initiation of 
labour compared to the normal pregnant controls. Vince et al (1995) found a significant 
correlation between the levels of IL-6 and TNF in pre-eclamptic patients and suggested 
that excess release of TNF may play a role in the pathology of pre-eclampsia. TNF was 
not consistently detected in the plasma from patients with pre-eclampsia in Vince's study. 
However, differences in the circulating receptors were more obvious. Measuring TNF 
receptors may therefore be a better marker of excessive TNF release in vivo rather than 
measuring TNF itself. The strong correlation between IL-6 levels and levels of TNF 
receptors suggest a complex interaction among different cytokines and their receptors in 
the development of pre-eclampsia. Although we found increased concentrations of IL-6 
in our pre-eclamptic patients we found no significant increase in TNFa production. 
However we did not measure the TNF receptor concentrations in our patients. TNFa 
may not have been detected in a single blood sample from our patients since it is released 
locally in small quantities and the half life of TNFa is only a few minutes, thus it may be 
difficult to measure in the circulation. Measuring the TNF-R concentrations may give 
more consistent results. Our results showing increased concentrations of IL-6 and IL-lra 
in patients with pre-eclampsia agree with previous reports that increased cytokine 
concentrations play a role in the mediation of inflammatory and immune responses, in 
this case contributing to the endothelial damage and dysfunction in pre-eclampsia.
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4 .3 .3  GM-CSF
The granulocyte-macrophage-stimulating factors are specific glycoproteins that control 
the production and function of granulocytes and macrophages (Metcalf et ah 1986). GM- 
CSF can stimulate mature neutrophils. Since neutrophils are activated in pre-eclampsia 
perhaps GM-CSF could play a role in this activation. However, we found no significant 
increase in the concentration of GM-CSF in our pre-eclamptic patients.
4 .3 .4  IL-8
The circulating concentrations of IL-8 were not increased in our patients with pre­
eclampsia. Tanaka et al (1993) found that IL-8 was captured by receptors on the 
endothelial surface, providing an adhesion-inducing signal to leucocyte subsets, and 
therefore IL-8 may not be detected in the maternal circulation in pre-eclampsia.
4 .4  General discussion
We have shown that the cytokines IL-6 and IL-lra and the cell adhesion molecules 
VCAM-1 and E-Selectin are increased in the maternal circulation in pre-eclampsia. The 
increased expression of the cell adhesion molecules could be partly responsible for the 
neutrophil activation which occurs in pre-eclampsia. Cytokines could also trigger 
neutrophil activation and cell adhesion on the endothelium. They are emerging as 
candidates for physiological adhesion triggers (Harlan and Liu, 1992) and could be partly 
responsible for the increased expression of cell adhesion molecules seen in pre­
eclampsia. Both HUYECS in culture and endothelial cells in the vessels of normal 
placenta express IL-6 receptors. Our results have shown, for the first time, that IL-6 can 
induce the expression of both VC AM-2 and E-Selectin mRNA on endothelial cells in 
vitro which was both time and dose dependent (Lyall et al. 1997). We have also shown 
that E-Selectin and VCAM-1 protein were induced on HUVECS following treatment with 
IL-6. It is only possible to assess the immunocytochemical staining semi-quantitatively. 
The endothelial cells did not express these adhesion molecules before treatment with IL-6 
so semi-quantitative analysis was straightforward. We used a VCAM-1 antibody when 
carrying out immunocytochemistry and a VC AM-2 cDNA. The VC AM-2 cDNA 
recognises the same sequences as VCAM-1.
Hession et al (1991) cloned a new form of human VCAM-1 which contained an 
additional immunoglobulin homologous domain. The long and short forms of VCAM-1 
could not be discriminated by Northern analysis but could be discriminated by reverse 
transcriptase polymerase chain reaction (RT-PCR). This explains why we only had one
83
transcript on the autoradiograph. Both the six and seven-domain forms of VCAM-1 
support the adhesion of several VLA-4 expressing cell lines indicating that domain 4 
(which is missing in the six-domain form of VCAM-1) is not essential to the binding of 
leucocytes to VCAM-1.
The expression of cell adhesion molecules is partly regulated by changes in 
cytokine concentrations. The expression of E-Selectin is regulated, in pait, by changes in 
the concentration of the cytokines IL-1 or TNFa whilst the expression of VCAM-1 is 
partly regulated by the cytokines IL-lp, IL-4, TNFa and IFNy (Masinovsky et al. 1990; 
Thornhill and Haskard, 1990). Our results suggest that the expression of VCAM-1 and 
E-Selectin is mediated partly by IL-6, levels of which increase significantly as gestation 
progresses in normal pregnancy (Opsjon etal, 1993). There may be an abnormal or “over 
rigourous” response to the increasing levels of IL-6 occurring in pre-eclampsia which in 
turn allows the cytokine to exert a pathological effect on the endothelium, increasing the 
expression of cell adhesion molecules so resulting in damage.
There are numerous studies which indicate that neutrophil activation occurs in pre­
eclampsia but the mechanism underlying this activation remains to be elucidated. The 
change in cell adhesion molecules and cytokines described in this thesis may be important 
components of the neutrophil activation process. In addition to this work we recently 
examined whether neutrophil activation, occurring in the maternal circulation of women 
with pre-eclampsia, was due to a factor in the plasma or serum which increased 
neutrophil locomotion (Clark et al. 1996a). The early stages of neutrophil recruitment 
require, not only changes in cell adhesion, but also motor capacity. The late stages of 
neutrophil recruitment are marked by dramatic activation of the cell metabolism. This 
study used a microcomputer-based system for real-time analysis of neutrophil behaviour 
in vitro. The results found no evidence of a humoral factor in the plasma/serum of 
women with pre-eclampsia which could alter the locomotion of human neutrophils. The 
results suggested that although IL-6 is increased in plasma from women with pre­
eclampsia it did not stimulate neutrophil motility directly. We also examined whether 
neutrophil activation in pre-eclampsia was due to a factor in the maternal serum which 
increased neutrophil adhesion to endothelial cells (Clark et al. 1997). Significantly 
increased adhesion of neutrophils to endothelial cells in response to IL-1 (3 and TNFa 
was shown, which confirmed a report by Bochner et al (1991). IL-6 did not stimulate 
neutrophil-endothelial cell adhesion. We have shown a dose and time dependent increase 
in E-Selectin and VC AM protein and mRNA on HUVECS in repsonse to IL-6. We 
would hypothesise that neutrophil adhesion increases the response to IL-6 due to the 
recruitment of E-Selectin onto the endothelium however this was not shown. IL-6 may be 
inactive at some stages of neutrophil activation. IL-6 has been reported to "prime" 
neutrophils, enhancing superoxide secretion by formyl-methionyl-leucyl-phenylalanine 
(FMLP)-treated neutrophils by over 50% (Borish et al. 1989). Bass et al (1986) termed
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the ability of a substance to potentiate the stimulated oxidative burst of a cell without 
directly stimulating a respiratory burst itself as "priming". IL-6 may mediate a respiratory 
burst which releases oxygen radicals and inflammatory mediators at the later stages of 
neutrophil activation but does not have a direct effect on neutrophil activation. Tsukimori 
et al (1993) found that FMLP-induced superoxide production of neutrophils was 
significantly higher in pre-eclamptics compared to normal pregnant women. When 
neutrophils prepared from normal non-pregnant women were incubated with sera from 
normal pregnant and pre-eclamptic women, the sera from the pre-eclamptics enhanced the 
FMLP-induced superoxide production to nearly twice that of the other subjects. Barden et 
aL(1997) measured basal neutrophil CD 11b (Mac-1) to assess neutrophil activation and 
found that neutrophil CD 11b was positively correlated with plasma uric acid levels 
suggesting that the extent of neutrophil activation correlates with disease severity in pre­
eclampsia. Perhaps plasma or serum from women with severe pre-eclampsia alters 
neutrophil locomotion or adhesion. From these results we can see that neutrophil 
activation occurs in pre-eclampsia but plays a small role in a complex disease process.
We have shown that the cell adhesion molecules VCAM-1 and E-Selectin and the 
cytokines IL-6 and IL-lra are increased in the maternal circulation in patients with pre­
eclampsia compared to normal pregnant controls. Furthermore we have shown that IL-6 
induces VC AM-2 and E-Selectin mRNA and protein expression although this is not the 
only factor necessary for increased neutrophil activation. Pre-eclampsia is a multisystem 
disorder characterized by vasculai' damage brought about by endothelial dysfunction and 
activation of platelets, neutrophils and the coagulation system. The presence of increased 
concentrations of VCAM-1, E-Selectin, IL-6 or IL-lra may all contribute to endothelial 
damage and dysfunction seen in this disorder but this is only one small part of a complex 
disease process. Effective diagnosis and treatment will only come as a result of a clearer 
understanding of the pathogenesis of the disease.
4 ,5  Future Work
In retrospect it would have been ideal to measure the soluble cell adhesion molecule and 
the soluble cytokine concentrations in both plasma and serum from women with pre­
eclampsia and determine why plasma and serum concentrations differ. In addition it could 
be useful to measure the soluble IL-6 concentration in maternal plasma throughout 
gestation to elucidate whether there was a specific time when IL-6 was significantly 
increased and whether this related to any changes in features in the pre-eclamptic patient 
or perhaps even trigger the onset of clinical symptoms. It would be potentially valuable to 
relate the increase in IL-6 to other specific factors. Are there any other clinical markers 
that relate to this increase in IL-6? We could measure soluble VCAM-1 and E-Selectin 
concentrations throughout gestation and again try to find out when the expression of
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these ceil adhesion molecules became significant. Is there a specific time when neutrophil 
activation occurs in pre-eclampsia? We have found a relationship between the cytokine 
IL-6 and the expression of VCAM-2 and E-Selectin. Does TNFot have the same effect on 
cell adhesion molecule expression or are there any other cytokines which stimulate cell 
adhesion molecule expression? We recently examined neutrophil locomotion and 
adhesion in vitro but found no evidence of a factor in the plasma or serum from pre­
eclamptic women which stimulated neutrophil activation. The HUVECS in our study 
were from control patients and the neutrophils from healthy non-pregnant women. We 
could examine the effects of neutrophils from pre-eclamptic women on adhesion to 
endothelial cells that have been incubated with pre-eclamptic serum or plasma.
Recent studies have suggested that a dysfunction in lipid and lipoprotein 
metabolism may contribute to endothelial cell dysfunction in pre-eclampsia (Hubei et al 
1996; Lorentzen et al 1994, 1995). The increased expression of cell adhesion molecules 
on the endothelium also contributes to endothelial dysfunction. We could study the effect 
of varying doses of lipoprotein particles and determine their potential for stimulating the 
expression of the adhesion molecules E-Selectin, ICAM, VC AM and PECAM.
NF-kB is a polypeptide which controls the transcription of genes. It is rapidly 
translocated from the cytoplasm to the nucleus in response to extracellular signals 
(Siebenlist etal, 1994). NF-kB has been shown to be involved in controlling a variety of 
genes involved in inflammation. It may therefore play a central role in the inflammatory 
response to infection and tissue injury in diseases such as toxic/septic shock, acute 
inflammatory conditions, atherosclerosis and cancer. It has been reported that cell 
adhesion molecules are regulated through NF-kB expression. Neish et al (1992) 
suggested that NF-kB-mediated activation of VCAM-1 gene expression may lead to 
endothelial expression of a mononuclear leucocyte adhesion molecule associated with 
initial events in the development of an atherosclerotic lesion. Manning et al (1995) found 
that NF-kB activation preceded the transcriptional activation of P-Selectin, E-Selectin, 
VCAM-1 and ICAM-1 genes in rat lung and heart tissues, when exposed to endotoxin. 
They suggested that NF-kB activation is an early event in the initiation of acute 
inflammation in vivo. A  study by Libermann and Baltimore (1990) suggested a role for 
NF-kB in the expression of the cytokine IL-6. They found that the promotor region of 
the IL-6 gene had a NF-kB binding site and mutations in the NF-kB binding site 
abolished inducibility of IL-6 in U-937 cells by lipopolysaccharides and TNFa. Satriano 
and Schlodorff (1994) found increased nuclear proteins bound to a NF-kB specific DNA 
oligonucleotide after mesangial cells were activated with TNFa. We have shown that 
increased expression of cytokines and cell adhesion molecules by the endothelium could 
be responsible for neutrophil activation which occurs in pre-eclampsia. NF-kB regulates 
these adhesion molecules and therefore may play a role in pre-eclampsia.
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